[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2486
1. Barbui T, Finazzi G: Evidence-based management of polycythemia vera. Best Pract Res Clin Haematol; 2006;19(3):483-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical course of polycythemia vera is marked by significant thrombotic complications and a variable risk of the disease turning either into myeloid metaplasia with myelofibrosis or into acute myeloid leukemia.
  • However, there is concern that certain myelosuppressive drugs accelerate the disease progression to acute leukemia.
  • Thus, the objective of management is two-fold: first, to minimize the risk of thrombotic complications; second, to prevent progression to myelofibrotic or leukemic transformation.
  • This chapter provides updated estimates of the risk of thrombosis and disease progression and evaluates the various randomized and observational studies in polycythemia vera, according to an evidence-based approach.

  • Genetic Alliance. consumer health - Polycythemia vera.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16781485.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Platelet Aggregation Inhibitors; X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 27
  •  go-up   go-down


2. Lillienberg L, Zock JP, Kromhout H, Plana E, Jarvis D, Torén K, Kogevinas M: A population-based study on welding exposures at work and respiratory symptoms. Ann Occup Hyg; 2008 Mar;52(2):107-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a 9-year follow-up study (ECRHS II), the aim was to study if welding at work increases the risk of asthma symptoms, wheeze and chronic bronchitis symptoms.
  • Log-binomial regression models were used to estimate prevalence ratios (PR) with 95% confidence intervals (CIs) for prevalence of asthma symptoms or asthma medication, wheeze and chronic bronchitis symptoms in relation to welding methods and welded materials as well as estimated cumulative welding fume exposure compared to an external reference group.
  • Welding at work was not associated with an increased prevalence of asthma symptoms or wheeze but there was an association with chronic bronchitis symptoms (PR = 1.33, 1.00-1.76).
  • Chronic bronchitis symptoms was significantly higher in those frequently welding in galvanized steel or iron (PR = 2.14, 1.24-3.68) and in those frequently manual welding stainless steel (PR = 1.92, 1.00-3.66).
  • There was also an increase in the prevalence of wheeze in individuals welding painted metal (PR = 1.66, 0.99-2.78; PR = 1.83, 0.90-3.71).
  • Welding with manual metal arc technique <1 day week(-1) showed a prevalence risk of 1.69 for wheeze (CI = 1.16-2.46).
  • In conclusion, the present study shows an association between welding in galvanized material and stainless steel and chronic bronchitis symptoms.
  • There was also an increased prevalence of wheeze and welding in painted metal.

  • MedlinePlus Health Information. consumer health - Asthma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18216372.001).
  • [ISSN] 1475-3162
  • [Journal-full-title] The Annals of occupational hygiene
  • [ISO-abbreviation] Ann Occup Hyg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational
  •  go-up   go-down


3. Taube F, Ylmén R, Shchukarev A, Nietzsche S, Norén JG: Morphological and chemical characterization of tooth enamel exposed to alkaline agents. J Dent; 2010 Jan;38(1):72-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphological and chemical characterization of tooth enamel exposed to alkaline agents.
  • OBJECTIVES: In this study, morphological and chemical changes in teeth enamel exposed to alkaline agents, with or without surfactants, have been investigated.
  • In addition, chemical effects of the organic surface layer, i.e. plaque and pellicle, were also investigated.
  • METHODS: The present study was conducted using several techniques: Fourier transform infrared spectroscopy (FTIR), X-ray photoelectron spectroscopy (XPS), X-ray diffraction (XRD) and scanning electron microscopy (SEM).
  • RESULTS: From XPS-measurements, it was found that exposure to alkaline solutions resulted in a massive removal of carbon from the tooth surface, and that the addition of surfactants increased the rate under present conditions.
  • Based on the results from the FTIR-analysis, no substitution reactions between phosphate, carbonate and hydroxide ions in the enamel apatite could be detected.
  • From a minor SEM-analysis, degradation and loss of substance of the enamel surface was found for the exposed samples.
  • From XRD-analysis, no changes in crystallinity of the enamel apatite could be found between the samples.
  • CONCLUSIONS: The findings in this study show that exposure to alkaline solutions results in a degradation of enamel surfaces very dissimilar from acidic erosion.
  • No significant erosion or chemical substitution of the apatite crystals themselves could be discerned.
  • However, significant loss of organic carbon at the enamel surface was found in all exposed samples.
  • The degradation of the protective organic layer at the enamel surface may profoundly increase the risk for caries and dental erosion from acidic foods and beverages.
  • [MeSH-major] Alkalies / pharmacology. Dental Enamel / drug effects. Hydroxides / pharmacology. Potassium Compounds / pharmacology
  • [MeSH-minor] Apatites / analysis. Calcium / analysis. Carbon / analysis. Carbonates / analysis. Crystallography. Dental Pellicle / chemistry. Dental Pellicle / drug effects. Dental Pellicle / ultrastructure. Dental Plaque / chemistry. Dental Plaque / pathology. Dental Plaque / physiopathology. Detergents / pharmacology. Humans. Microscopy, Electron, Scanning. Phosphates / analysis. Phosphorus / analysis. Photoelectron Spectroscopy. Spectroscopy, Fourier Transform Infrared. Sulfuric Acids / pharmacology. Surface-Active Agents / pharmacology. Tooth Demineralization / metabolism. Tooth Demineralization / pathology. Tooth Demineralization / physiopathology. X-Ray Diffraction

  • Hazardous Substances Data Bank. POTASSIUM HYDROXIDE .
  • Hazardous Substances Data Bank. CARBON .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. Sulfuric acid .
  • Hazardous Substances Data Bank. PHOSPHORUS, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781592.001).
  • [ISSN] 1879-176X
  • [Journal-full-title] Journal of dentistry
  • [ISO-abbreviation] J Dent
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkalies; 0 / Apatites; 0 / Carbonates; 0 / Detergents; 0 / Hydroxides; 0 / Phosphates; 0 / Potassium Compounds; 0 / Sulfuric Acids; 0 / Surface-Active Agents; 27YLU75U4W / Phosphorus; 7440-44-0 / Carbon; 9159UV381P / hydroxide ion; O40UQP6WCF / sulfuric acid; SY7Q814VUP / Calcium; WZH3C48M4T / potassium hydroxide
  •  go-up   go-down


Advertisement
4. Rosenblatt NJ, Grabiner MD: Measures of frontal plane stability during treadmill and overground walking. Gait Posture; 2010 Mar;31(3):380-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently the "margin of stability" (MOS) has been adopted for describing dynamic stability.
  • Although these measures may be influenced by the conditions during which locomotion occurs, only one published within-subject study has compared SW (but not SWV or MOS) during overground and treadmill walking.
  • Therefore, we compared SW, SWV and minimum MOS (MOS(min)) in 10 healthy young subjects walking at self-selected speeds, both overground and on a treadmill.
  • In contrast, MOS(min) was insensitive to treadmill versus overground walking.
  • This suggested first, that SW and SWV only partially reflect frontal plane stability, and second, that the goal of the central nervous system may be to maintain a constant MOS(min) regardless of task.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20129786.001).
  • [ISSN] 1879-2219
  • [Journal-full-title] Gait & posture
  • [ISO-abbreviation] Gait Posture
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Wang G, Eyden B, Yao LF, Chen SZ, Banerjee SS: Primary small cell malignant melanoma of the rectum: case report of a very rare tumor. Ultrastruct Pathol; 2007 Jul-Aug;31(4):315-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small cell malignant melanoma of the rectum: case report of a very rare tumor.
  • Rectal/anorectal malignant melanomas are highly aggressive tumors with a poor prognosis and low 5-year survival rate.
  • Of the well-known histological variants of malignant melanoma, the small cell subtype is also very uncommon; consequently, small cell anorectal malignant melanoma is an exceedingly rare occurrence.
  • In this article, the authors provide a detailed clinicopathological description of small cell malignant melanoma of the rectum, documenting clinical, histological, immunohistochemical, and ultrastructural features, to add to the sparse references on this tumor in the literature.
  • The patient was a 53-year-old woman with a mass 2 cm from the anus, which was surgically removed.
  • In histological sections, the tumor was a small cell malignant melanoma, with a tumor cell diameter of 7.6+/-1.0 microm, and a range of 5.5-10.7 microm (N = 100).
  • This article is one of the few detailed clinicopathological documentations of a small cell malignant melanoma of the rectum (anorectum) and the first to have the diagnosis confirmed ultrastructurally by the identification of melanosomes.
  • The present case adds to the 3 mainly or entirely small cell anorectal malignant melanomas described in the literature.
  • Documentation of these unusual morphological variants is important for identifying any distinctive outcome they might exhibit compared with conventional malignant melanoma.
  • [MeSH-major] Melanoma / ultrastructure. Rectal Neoplasms / ultrastructure
  • [MeSH-minor] Antigens, Neoplasm. Female. Humans. Immunohistochemistry. Melanoma-Specific Antigens. Microscopy, Electron, Transmission. Middle Aged. Neoplasm Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17786832.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


6. Thachil J: The enigma of pulmonary hypertension after splenectomy--does the megakaryocyte provide a clue? QJM; 2009 Oct;102(10):743-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is particularly so in haemolytic diseases like thalassaemia and myeloproliferative conditions like idiopathic myelofibrosis.


7. Perret-Guillaume C, Briancon S, Guillemin F, Wahl D, Empereur F, Nguyen Thi PL: Which generic health related Quality of Life questionnaire should be used in older inpatients: comparison of the Duke Health Profile and the MOS Short-Form SF-36? J Nutr Health Aging; 2010 Apr;14(4):325-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Which generic health related Quality of Life questionnaire should be used in older inpatients: comparison of the Duke Health Profile and the MOS Short-Form SF-36?
  • DESIGN: Two validated generic health-related Quality of Life instruments : the MOS Short-Form 36 (9 dimensions, 36 items) and the Duke Health Profile (6 dimensions, 4 dysfunctions, 17 items) were administered to inpatients over 65 years.

  • MedlinePlus Health Information. consumer health - Mental Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Health Care Financ Rev. 2004 Summer;25(4):5-25 [15493441.001]
  • [Cites] J Clin Epidemiol. 1998 Oct;51(10):827-35 [9762875.001]
  • [Cites] J Epidemiol Community Health. 1996 Feb;50(1):94-8 [8762362.001]
  • [Cites] Dement Geriatr Cogn Disord. 2001 Mar-Apr;12(2):158-66 [11173890.001]
  • [Cites] J Clin Epidemiol. 2003 Feb;56(2):138-47 [12654408.001]
  • [Cites] Age Ageing. 2001 Jul;30(4):337-43 [11509313.001]
  • [Cites] Med Care. 1990 Nov;28(11):1056-72 [2250492.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • [Cites] Med Care. 1991 Jul;29(7):679-83 [2072773.001]
  • [Cites] Psychol Bull. 1959 Mar;56(2):81-105 [13634291.001]
  • [Cites] Qual Life Res. 2005 Dec;14(10):2197-214 [16328900.001]
  • [Cites] Med Care. 1996 Dec;34(12):1165-70 [8962582.001]
  • [Cites] BMJ. 2002 Jun 15;324(7351):1417 [12065262.001]
  • [Cites] Rev Epidemiol Sante Publique. 1995;43(4):371-9 [7667543.001]
  • [Cites] Health Qual Life Outcomes. 2003 Jul 03;1:24 [12848895.001]
  • [Cites] Stat Med. 1995 Dec 15;14(23):2565-80 [8746889.001]
  • [Cites] Qual Life Res. 2005 Sep;14(7):1651-68 [16119178.001]
  • [Cites] BMJ. 1998 Oct 31;317(7167):1191-4 [9794853.001]
  • [Cites] Sante Publique. 1997 Mar;9(1):35-44 [9432414.001]
  • [Cites] J Eval Clin Pract. 2005 Aug;11(4):315-27 [16011644.001]
  • [Cites] Age Ageing. 1998 Jan;27(1):13-8 [9504361.001]
  • [Cites] Joint Bone Spine. 2001 Dec;68(6):499-503 [11808987.001]
  • [Cites] Fam Med. 1993 Sep;25(8):536-9 [8405803.001]
  • (PMID = 20306007.001).
  • [ISSN] 1760-4788
  • [Journal-full-title] The journal of nutrition, health & aging
  • [ISO-abbreviation] J Nutr Health Aging
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


8. Trunzo JA, McHenry CR, Schulak JA, Wilhelm SM: Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism. Surgery; 2008 Dec;144(6):915-8; discussion 919
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism.
  • BACKGROUND: It has been suggested that parathyroidectomy for hyperparathyroidism (HPT) in end-stage renal disease (ESRD) may result in improvement in anemia and the response to erythropoiesis-stimulating drugs.
  • Other data collections were at 1 and 2 mos. postoperatively.
  • RESULTS: Thirty-seven patients met inclusion criteria.
  • Hb and Hct levels followed an upward trend at 12 mos (11.4 +/- 0.3 to 12.1 +/- 0.2 g/dL and 35.7 +/- 1.0 to 37.1 +/- 0.6%, respectively).
  • As a result, we propose refractory ESRD-associated anemia as a secondary indication for parathyroidectomy resection in this population.
  • [MeSH-major] Anemia / drug therapy. Erythropoietin / administration & dosage. Hematinics / administration & dosage. Hyperparathyroidism, Secondary / surgery. Kidney Failure, Chronic / complications. Parathyroidectomy


9. Iezzoni LI, Rao SR, Kinkel RP: Experiences acquiring and using mobility aids among working-age persons with multiple sclerosis living in communities in the United States. Am J Phys Med Rehabil; 2010 Dec;89(12):1010-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite owning mobility aids, many had not used this equipment in the previous 12 mos, including 4.5% of power wheelchair owners, 13.8% of those with manual wheelchairs, and 9.3% of scooter owners.


10. Rai P, Lee BM, Liu TY, Yuhui Q, Krause E, Marsman DS, Felter S: Safety evaluation of disposable baby diapers using principles of quantitative risk assessment. J Toxicol Environ Health A; 2009;72(21-22):1262-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The safety profile of a diaper is determined by the biological properties of individual components and the extent to which the baby is exposed to each component during use.
  • This assessment of potential exposure is then combined with data from standard safety assessments of components to determine the margin of safety (MOS).

  • Hazardous Substances Data Bank. CITRAL .
  • Hazardous Substances Data Bank. SODIUM ACRYLATE .
  • Hazardous Substances Data Bank. Acrylic acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20077195.001).
  • [ISSN] 1528-7394
  • [Journal-full-title] Journal of toxicology and environmental health. Part A
  • [ISO-abbreviation] J. Toxicol. Environ. Health Part A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Acrylates; 0 / Monoterpenes; 0 / Perfume; J94PBK7X8S / acrylic acid; T7EU0O9VPP / citral
  •  go-up   go-down


11. Johnson ES, Zhou Y, Lillian Yau C, Prabhakar D, Ndetan H, Singh K, Preacely N: Mortality from malignant diseases-update of the Baltimore union poultry cohort. Cancer Causes Control; 2010 Feb;21(2):215-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality from malignant diseases-update of the Baltimore union poultry cohort.
  • We previously studied mortality up to 1989 in 2,639 members of a local union who had ever worked in poultry slaughtering and processing plants, because they were exposed to oncogenic viruses present in poultry.
  • Compared to the US general population, an excess of cancers of the buccal and nasal cavities and pharynx (base of the tongue, palate and other unspecified mouth, tonsil and oropharynx, nasal cavity/middle ear/accessory sinus), esophagus, recto-sigmoid/rectum/anus, liver and intrabiliary system, myelofibrosis, lymphoid leukemia and multiple myeloma was observed in particular subgroups or in the entire poultry cohort.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847658.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 R01 CA 30410-3; United States / NIOSH CDC HHS / OH / 1 R01 OH008071
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  •  go-up   go-down


12. Ruiz-Pérez I, Olry de Labry-Lima A, López-Ruz MA, del Arco-Jiménez A, Rodríguez-Baño J, Causse-Prados M, Pasquau-Liaño J, Martín-Rico P, Prada-Pardal JL, de la Torre-Lima J, López-Gómez M, Marcos M, Muñoz N, Morales D, Muñoz I: [Clinical status, adherence to HAART and quality of life in HIV-infected patients receiving antiretroviral treatment]. Enferm Infecc Microbiol Clin; 2005 Dec;23(10):581-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Estado clínico, adherencia al TARGA y calidad de vida en pacientes con infección por el VIH tratados con antirretrovirales.
  • INTRODUCTION: Quality of life is one of the most frequently used subjective measures in chronic health problems.
  • Health-related quality of life was assessed with the MOS-HIV questionnaire, an instrument designed specifically for HIV-infected patients.
  • No statistically significant differences in the domain scores except for quality of life were found between patients with a treatment regimen including protease inhibitors and those without.


13. Matsuoka H, Nakamura A, Iwamoto K, Sugiyama M, Hachiya J, Atomi Y, Masaki T: Anorectal malignant melanoma: preoperative usefulness of magnetic resonance imaging. J Gastroenterol; 2005 Aug;40(8):836-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anorectal malignant melanoma: preoperative usefulness of magnetic resonance imaging.
  • Magnetic resonance imaging (MRI) findings in three patients with primary anorectal malignant melanoma are described.
  • Two patients had melanotic and one had amelanotic anorectal melanoma.
  • The findings of MRI with a pelvic coil and an endorectal coil were consistent with pathologic findings.
  • MRI with a pelvic coil demonstrated the melanotic component as high signal intensity on T1-weighted imaging.
  • MRI with a pelvic coil and an endorectal coil was useful for staging anorectal melanoma.
  • This article describes the initial report of the use of an endorectal coil for malignant melanoma of the anorectum.
  • [MeSH-major] Anus Neoplasms / diagnosis. Magnetic Resonance Imaging. Melanoma, Amelanotic / diagnosis. Rectal Neoplasms / diagnosis. Sarcoma, Clear Cell / diagnosis

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1997 Jun;40(6):661-8 [9194459.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4097-101 [15736458.001]
  • [Cites] Surg Today. 2003;33(3):209-13 [12658389.001]
  • [Cites] Surg Today. 1999;29(2):170-3 [10030744.001]
  • [Cites] Dis Colon Rectum. 2000 Mar;43(3):338-45 [10733115.001]
  • [Cites] Br J Radiol. 1999 Jan;72(853):18-23 [10341684.001]
  • [Cites] Eur J Radiol. 1993 Apr;16(3):195-7 [8508834.001]
  • [Cites] J Magn Reson Imaging. 1993 Mar-Apr;3(2):329-35 [8448394.001]
  • [Cites] Hepatogastroenterology. 2004 Jan-Feb;51(55):131-5 [15011848.001]
  • [Cites] Dis Colon Rectum. 1995 Feb;38(2):146-51 [7851168.001]
  • [Cites] Am J Surg. 2003 Apr;185(4):328-32 [12657384.001]
  • [Cites] Dis Colon Rectum. 2002 Oct;45(10 ):1412-5; discussion 1415-7 [12394445.001]
  • [Cites] Cancer. 1981 Apr 1;47(7):1891-900 [6164474.001]
  • [Cites] Radiology. 1999 Apr;211(1):215-22 [10189474.001]
  • (PMID = 16143890.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


14. Bucciardini R, Fragola V, Massella M, Polizzi C, Mirra M, Goodall R, Carey D, Hudson F, Zajdenverg R, Floridia M, Initio Trial International Coordinating Committee: Health-related quality of life outcomes in HIV-infected patients starting different combination regimens in a randomized multinational trial: the INITIO-QoL substudy. AIDS Res Hum Retroviruses; 2007 Oct;23(10):1215-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HRQoL was measured in a subgroup of patients enrolled in the INITIO study (153/911), using a modified version of the MOS-HIV questionnaire.
  • Primary HRQoL outcomes were Physical and Mental Health Summary scores (PHS and MHS, respectively).
  • Overall, starting all the combination regimens compared in the INITIO study was associated with a maintained or slightly improved HRQOL status, consistently with the positive immunological and virological changes observed in the main study.


15. Nurden AT: Qualitative disorders of platelets and megakaryocytes. J Thromb Haemost; 2005 Aug;3(8):1773-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Qualitative disorders of platelet function and production form a large group of rare diseases which cover a multitude of genetic defects that by and large have as a common symptom, excessive mucocutaneous bleeding.
  • Bernard-Soulier syndrome, an example of macrothrombocytopenia, combines the production of large platelets with a deficit or non-functioning of the major adhesion receptor of platelets, the GPIb-IX-V complex.
  • Amino acid substitutions in GPIb alpha, may lead to up-regulation and spontaneous binding of von Willebrand factor as in Platelet-type von Willebrand disease.
  • In disorders with defects in the MYH9 gene, macrothrombocytopenias are linked to modifications in kidney, eye or ear, whereas other inherited thrombocytopenias variously link a low platelet count with a propensity to leukemia, skeletal defects, learning impairment, and abnormal red cells.
  • Defects of secretion from platelets include an abnormal alpha-granule formation as in the gray platelet syndrome (with marrow myelofibrosis), and of organelle biogenesis in the Hermansky-Pudlak and Chediak-Higashi syndromes where platelet dense body defects are linked to abnormalities of other lysosomal-like organelles including melanosomes.
  • Finally, defects involving surface receptors (P2Y(12), TPalpha) for activating stimuli, of proteins essential for signaling pathways (including Wiskott-Aldrich syndrome), and of platelet-derived procoagulant activity (Scott syndrome) show how studies on platelet disorders are helping unravel the pathways of primary hemostasis.
  • [MeSH-major] Blood Platelet Disorders / blood. Blood Platelet Disorders / diagnosis. Megakaryocytes / physiology

  • MedlinePlus Health Information. consumer health - Platelet Disorders.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16102044.001).
  • [ISSN] 1538-7933
  • [Journal-full-title] Journal of thrombosis and haemostasis : JTH
  • [ISO-abbreviation] J. Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coagulants; 0 / Integrins; 0 / von Willebrand Factor
  • [Number-of-references] 100
  •  go-up   go-down


16. Sikkeland LI, Haug T, Stangeland AM, Flatberg G, Søstrand P, Halvorsen B, Kongerud J: Airway inflammation in paper mill workers. J Occup Environ Med; 2007 Oct;49(10):1135-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Paper mill workers are exposed to culturable microorganisms (MOs).
  • Workers exposed to high levels of MOs (HMOE, n = 17) were compared with workers exposed to low levels of MO (LMOE, n = 12).
  • Our findings indicate that paper industry workers exposed to MOs develop subclinical airway inflammation.


17. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, Kiladijan JJ, Lengfelder E, Mesa R, Mc Mullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T: A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol; 2010 Mar;148(6):961-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Resistance. Hydroxyurea / therapeutic use. Polycythemia Vera / drug therapy. Primary Myelofibrosis / drug therapy


18. Milgrom P, Ly KA, Roberts MC, Rothen M, Mueller G, Yamaguchi DK: Mutans streptococci dose response to xylitol chewing gum. J Dent Res; 2006 Feb;85(2):177-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Samples were taken at baseline, 5 wks, and 6 mos, and were cultured on modified Mitis Salivarius agar for mutans streptococci and on blood agar for total culturable flora.
  • At 6 mos, mutans streptococci in plaque for G3 and G4 remained 10x lower than baseline (P = 0.007/0.04).
  • Xylitol at 6.44 g/day and 10.32 g/day reduces mutans streptococci in plaque at 5 wks, and in plaque and unstimulated saliva at 6 mos.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Xylitol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Caries Res. 1991;25(2):153-7 [2059978.001]
  • [Cites] Caries Res. 1989;23(4):261-7 [2790861.001]
  • [Cites] Caries Res. 1989;23(5):378-84 [2766327.001]
  • [Cites] Caries Res. 1987;21(2):109-16 [3469026.001]
  • [Cites] Acta Pathol Microbiol Immunol Scand B. 1986 Apr;94(2):97-102 [3728029.001]
  • [Cites] J Am Dent Assoc. 1984 Apr;108(4):587-92 [6427315.001]
  • [Cites] J Dent Res. 1983 Aug;62(8):882-4 [6575035.001]
  • [Cites] Eur J Oral Sci. 2004 Jun;112(3):244-8 [15154922.001]
  • [Cites] Oral Microbiol Immunol. 2003 Aug;18(4):215-9 [12823796.001]
  • [Cites] J Am Dent Assoc. 2002 Apr;133(4):435-41; quiz 492-3 [11991460.001]
  • [Cites] J Oral Rehabil. 1997 May;24(5):325-31 [9183024.001]
  • [Cites] Eur J Oral Sci. 2000 Dec;108(6):538-45 [11153929.001]
  • [Cites] Caries Res. 1996;30(3):180-8 [8860027.001]
  • [Cites] J Dent Res. 1995 Dec;74(12):1904-13 [8600188.001]
  • [Cites] Int Dent J. 1995 Feb;45(1 Suppl 1):65-76 [7607747.001]
  • [Cites] Am J Orthod Dentofacial Orthop. 1995 May;107(5):497-504 [7733059.001]
  • [Cites] Caries Res. 1994;28(1):48-54 [8124697.001]
  • [Cites] Oral Microbiol Immunol. 1991 Oct;6(5):275-9 [1820563.001]
  • (PMID = 16434738.001).
  • [ISSN] 0022-0345
  • [Journal-full-title] Journal of dental research
  • [ISO-abbreviation] J. Dent. Res.
  • [Language] eng
  • [Grant] United States / NIDCR NIH HHS / DE / U54 DE014254; United States / NIDCR NIH HHS / DE / U54 DE014254-01; United States / NIDCR NIH HHS / DE / U54DE14254
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chewing Gum; 0 / Sweetening Agents; VCQ006KQ1E / Xylitol
  • [Other-IDs] NLM/ NIHMS38029; NLM/ PMC2225984
  •  go-up   go-down


19. Hasselbalch HC, Birgens H, Dufva IH, Dalseg AM, Brown Pde N, Jensen MK, Vangsted A: [Novel medical treatment modalities in hematology]. Ugeskr Laeger; 2008 Jun 9;170(24):2115-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Today several monoclonal antibodies, including the anti-CD20 antibody (rituximab), the anti-CD52 antibody (alemtuzumab) and the anti-CD33 antibody (gemtuzumab ozogamacin) are all integrated in the therapeutic armamentarium of patients with malignant lymphoma, chronic lymphocytic leukaemia and acute myelogenous leukaemia, respectively.
  • Rituximab has also been shown to be highly effective in the treatment of refractory autoimmune haemolytic anemias, idiopathic thrombocytopenia, and relapsing thrombotic thrombocytopenic purpura.
  • New signal transduction inhibitors, dasatinib and nilotinib, are being used in patients with chronic myelogeneous leukaemia who develop resistance to imatinib.
  • Thalidomide, lenalidomide and bortezomib have all been shown to be highly effective in multiple myeloma, and JAK2-inhibitors have entered phase II studies of patients with JAK2-positive primary myelofibrosis and related diseases.
  • [MeSH-minor] Aminoglycosides / therapeutic use. Anemia, Hemolytic / drug therapy. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Benzamides. Benzoates / therapeutic use. Boronic Acids / therapeutic use. Bortezomib. Carbazoles / therapeutic use. Carrier Proteins / therapeutic use. Cyclophosphamide / therapeutic use. Dasatinib. Humans. Hydrazines / therapeutic use. Imatinib Mesylate. Indoles / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Multiple Myeloma / drug therapy. Myelodysplastic Syndromes / drug therapy. Piperazines / therapeutic use. Purpura, Thrombocytopenic / drug therapy. Pyrazines / therapeutic use. Pyrazoles / therapeutic use. Pyrimidines / therapeutic use. Receptors, Fc / therapeutic use. Recombinant Fusion Proteins. Rituximab. Thalidomide / analogs & derivatives. Thalidomide / therapeutic use. Thiazoles / therapeutic use. Thrombopoietin. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565291.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Benzoates; 0 / Boronic Acids; 0 / Carbazoles; 0 / Carrier Proteins; 0 / Hydrazines; 0 / Immunologic Factors; 0 / Indoles; 0 / Piperazines; 0 / Pyrazines; 0 / Pyrazoles; 0 / Pyrimidines; 0 / Receptors, Fc; 0 / Recombinant Fusion Proteins; 0 / Thiazoles; 0 / eltrombopag; 0 / gemtuzumab; 0 / romiplostim; 4F4X42SYQ6 / Rituximab; 4Z8R6ORS6L / Thalidomide; 639089-54-6 / VX680; 69G8BD63PP / Bortezomib; 8A1O1M485B / Imatinib Mesylate; 8N3DW7272P / Cyclophosphamide; 9014-42-0 / Thrombopoietin; A3ULP0F556 / eculizumab; DO989GC5D1 / lestaurtinib; F0P408N6V4 / lenalidomide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; RBZ1571X5H / Dasatinib
  • [Number-of-references] 40
  •  go-up   go-down


20. Queenan JA, Feldman-Stewart D, Brundage M, Groome PA: Social support and quality of life of prostate cancer patients after radiotherapy treatment. Eur J Cancer Care (Engl); 2010 Mar;19(2):251-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted a cross-sectional survey and a detailed chart review.
  • Functional social support was measured by using the MOS Social Support Survey.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19552729.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


21. Teofili L, Martini M, Cenci T, Petrucci G, Torti L, Storti S, Guidi F, Leone G, Larocca LM: Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood; 2007 Jul 1;110(1):354-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation.
  • The V617F JAK2 mutation reported in Ph-negative myeloproliferative diseases (MPDs) induces the constitutive activation of JAK2, which produces an increased phosphorylation of signal transducer activator of transcription (STAT).
  • In this study, we have analyzed a series of 114 patients (54 with polycythemia vera [PV], 44 with essential thrombocythemia [ET], 12 with idiopathic myelofibrosis [IM], and 4 with myelofibrosis secondary to MPD) for the expression pattern of phosphorylated STAT-3 and STAT-5 (pSTAT-3 and pSTAT-5, respectively) by immunostaining bone marrow biopsies.
  • These findings underline the importance of bone marrow histology in the differential diagnosis of Ph-negative MPD and support the hypothesis that V617F mutation simply contributes with other molecular defects in allowing the PV, ET, or IM phenotype to emerge.
  • [MeSH-major] Janus Kinase 2 / genetics. Myeloproliferative Disorders / diagnosis. Philadelphia Chromosome. STAT3 Transcription Factor / metabolism. STAT5 Transcription Factor / metabolism
  • [MeSH-minor] Bone Marrow Examination. Diagnosis, Differential. Humans. Phosphorylation. Point Mutation. Polycythemia Vera / diagnosis. Primary Myelofibrosis / diagnosis. Thrombocythemia, Essential / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17376889.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / STAT5 Transcription Factor; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


22. Oh TH, Stueve MH, Hoskin TL, Luedtke CA, Vincent A, Moder KG, Thompson JM: Brief interdisciplinary treatment program for fibromyalgia: six to twelve months outcome. Am J Phys Med Rehabil; 2010 Feb;89(2):115-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the impact and long-term benefit of a brief 1(1/2)-day fibromyalgia treatment program.
  • We administered three self-reported instruments: the Fibromyalgia Impact Questionnaire, the Short Form-36 Health Status Questionnaire, and a satisfaction survey, at baseline, and 6-12 mos after completing the fibromyalgia treatment program.
  • CONCLUSIONS: A brief 1(1/2)-day fibromyalgia treatment program improves symptoms and quality of life in patients with fibromyalgia for 6-12 mos.

  • Genetic Alliance. consumer health - Fibromyalgia.
  • MedlinePlus Health Information. consumer health - Fibromyalgia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090427.001).
  • [ISSN] 1537-7385
  • [Journal-full-title] American journal of physical medicine & rehabilitation
  • [ISO-abbreviation] Am J Phys Med Rehabil
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Tangen E, Conradie J, Ghosh A: The challenge of being straight: explaining the linearity of a low-spin [FeNO]7 unit in a tropocoronand complex. Inorg Chem; 2005 Nov 28;44(24):8699-706
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The challenge of being straight: explaining the linearity of a low-spin [FeNO]7 unit in a tropocoronand complex.
  • The calculations accurately reproduce the experimentally observed trigonal-bipyramidal geometry of this complex, featuring a linear NO in an equatorial position and a very short Fe-N(NO) distance.
  • Thus, there is a close correspondence between the molecular orbitals (MOs) in the two cases.
  • However, there is a critical, if somewhat subtle, difference in the nature of the singly occupied MOs (SOMOs) between the two.
  • Apparently, such a d orbital is less adept at sigma bonding with NO and, as such, pi bonding dominates the Fe-NO interaction, leading to an essentially linear FeNO unit and a short Fe-N(NO) distance.
  • [MeSH-major] Ferric Compounds / chemistry. Models, Molecular. Nitric Oxide / chemistry. Porphyrins / chemistry

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16296823.001).
  • [ISSN] 0020-1669
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ferric Compounds; 0 / Ligands; 0 / Porphyrins; 31C4KY9ESH / Nitric Oxide; 42VZT0U6YR / Heme
  •  go-up   go-down


24. Pineda RH, Heiser RA, Ribera AB: Developmental, molecular, and genetic dissection of INa in vivo in embryonic zebrafish sensory neurons. J Neurophysiol; 2005 Jun;93(6):3582-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MOs were injected into one-cell stage embryos, and RB sodium currents were recorded using patch-clamp techniques in both conventional whole cell mode as well from nucleated patches.
  • These results indicate that MOs are a useful tool for the molecular dissection and analysis of ion channel function in vivo.

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. TETRODOTOXIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. ZFIN: Data: Gene Expression .
  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15673553.001).
  • [ISSN] 0022-3077
  • [Journal-full-title] Journal of neurophysiology
  • [ISO-abbreviation] J. Neurophysiol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS-38937
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligodeoxyribonucleotides, Antisense; 0 / Sodium Channel Blockers; 0 / Sodium Channels; 4368-28-9 / Tetrodotoxin
  •  go-up   go-down


25. Biggs P, Parsons CM: The effects of several oligosaccharides on true amino acid digestibility and true metabolizable energy in cecectomized and conventional roosters. Poult Sci; 2007 Jun;86(6):1161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The dietary treatments consisted of a corn-isolated soy protein control diet or that diet supplemented with 4 or 8 g/kg of inulin, oligofructose, mannanoligosaccharide (MOS), short-chain fructooligosaccharide, or transgalactooligosaccharide (TOS).
  • The true digestibility of lysine and valine was increased (P<0.05) in cecectomized roosters fed 8 g/kg of MOS or TOS when compared with roosters fed the control diet.
  • In addition, methionine digestibility was improved (P<0.05) in cecectomized roosters fed 4 g/kg of MOS or short-chain fructooligosaccharide and by 8 g/kg of oligofructose or TOS.
  • The true digestibility of isoleucine was increased (P<0.05) in cecectomized roosters fed 8 g/kg of MOS or 4 or 8 g/kg of TOS.
  • The digestibility of a few amino acids, however, was increased by some oligosaccharides in cecectomized roosters but not in intact roosters.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495087.001).
  • [ISSN] 0032-5791
  • [Journal-full-title] Poultry science
  • [ISO-abbreviation] Poult. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Oligosaccharides
  •  go-up   go-down


26. Lau DT, Morlock RJ, Hill CD: Psychometric evaluation of the medical outcomes study-sleep scale in persons with overactive bladder. Clin Ther; 2006 Dec;28(12):2119-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The Medical Outcomes Study-Sleep Scale (MOS-SS) is a commonly used self-reported instrument for assessing key constructs of sleep quality and quantity.
  • Even though the MOS-SS has successfully undergone previous validation studies in the general population, it has not been evaluated in patients with overactive bladder (OAB).
  • OBJECTIVE: The aim of this study is to evaluate the applicability of the MOS-SS to persons with a diagnosis of OAB.
  • Analyses were then undertaken to assess the psychometric properties of the MOS-SS in this OAB sample.
  • Psychometric evaluation of the MOS-SS included construct validity, internal consistency reliability, correlation between domains, floor/ceiling effects, and an examination of the factor structure.
  • Results were compared with the original validation population of the MOS-SS by .
  • Factor loadings of the MOS-SS items, as well as tests of construct validity, were similar between persons with OAB and individuals in the original validation population.
  • CONCLUSION: Psychometric evaluation conducted in this study supports the use of the MOS-SS instrument to assess sleep problems among persons with OAB.

  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296468.001).
  • [ISSN] 0149-2918
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Petroianu A, Cabezas-Andrade MA, Neto RB: Laparoscopic splenic autotransplantation. Surg Laparosc Endosc Percutan Tech; 2006 Aug;16(4):259-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since 1990, we have performed splenic autotransplantation in more than 100 patients to treat splenic trauma, portal hypertension, myeloid metaplasia due to myelofibrosis, chronic lymphocytic leukemia, and Gaucher disease.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921309.001).
  • [ISSN] 1530-4515
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


28. Landry-Schönbeck A, de Grandmont P, Rompré PH, Lavigne GJ: Effect of an adjustable mandibular advancement appliance on sleep bruxism: a crossover sleep laboratory study. Int J Prosthodont; 2009 May-Jun;22(3):251-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The objective of this experimental study was to assess the efficacy and safety of a reinforced adjustable mandibular advancement appliance (MAA) on sleep bruxism (SB) activity compared to baseline and to a mandibular occlusal splint (MOS) in order to offer an alternative to patients with both tooth grinding and respiratory disorders during sleep.
  • After habituation and baseline nights, 3 more nights were spent with an MAA in either a slight (25%) or pronounced (75%) mandibular protrusion position or with an MOS (control).
  • The MOS slightly reduced the number of SB episodes per hour without reaching statistical significance (34%, P = .07).
  • CONCLUSION: Short-term use of an MAA is associated with a significant reduction in SB motor activity without any appliance breakage.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19548407.001).
  • [ISSN] 0893-2174
  • [Journal-full-title] The International journal of prosthodontics
  • [ISO-abbreviation] Int J Prosthodont
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Boulet T, Pavie J, Charreau I, Braun J, Reynes J, Morlat P, Piroth L, Spire B, Molina JM, Aboulker JP, Easier-Anrs 138 Study Group: Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138). HIV Clin Trials; 2010 Sep-Oct;11(5):283-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138).
  • HRQoL was assessed at baseline and weeks 24 and 48 using a self-report MOS-HIV questionnaire.


30. Honaga K, Masakado Y, Oki T, Hirabara Y, Fujiwara T, Ota T, Kimura A, Liu M: Associated reaction and spasticity among patients with stroke. Am J Phys Med Rehabil; 2007 Aug;86(8):656-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: The participants were ten patients with hemiparetic stroke, mean age of 65.2 yrs, and duration of stroke of 13.3 mos.
  • Simultaneously, we measured M-, H-, and T-wave amplitudes and calculated H/M and T/M in the paretic arm.
  • RESULTS: The AR ratio correlated significantly with MAS (P < 0.01), whereas H/M and T/M did not.

  • Genetic Alliance. consumer health - Spasticity.
  • MedlinePlus Health Information. consumer health - Stroke.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667196.001).
  • [ISSN] 0894-9115
  • [Journal-full-title] American journal of physical medicine & rehabilitation
  • [ISO-abbreviation] Am J Phys Med Rehabil
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


31. Bogani C, Guglielmelli P, Antonioli E, Pancrazzi A, Bosi A, Vannucchi AM: B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. Haematologica; 2007 Feb;92(2):258-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis.
  • An acquired JAK2 (V617F)mutation has been found in myeloid cells from most patients with chronic idiopathic myelofibrosis (IM), but whether it occurs in a common myelo-lymphoid, rather than a myeloid-restricted, progenitor cell is still debated.
  • [MeSH-major] B-Lymphocytes / cytology. Janus Kinase 2 / genetics. Killer Cells, Natural / cytology. Mutation. Primary Myelofibrosis / blood. Primary Myelofibrosis / genetics. T-Lymphocytes / cytology

  • Genetic Alliance. consumer health - Myelofibrosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296581.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / DNA, Complementary; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


32. Danilov AV, Relias V, Feeney DM, Miller KB: Decitabine is an effective treatment of idiopathic myelofibrosis. Br J Haematol; 2009 Apr;145(1):131-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decitabine is an effective treatment of idiopathic myelofibrosis.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Azacitidine / analogs & derivatives. DNA Modification Methylases / antagonists & inhibitors. Primary Myelofibrosis / drug therapy

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19133981.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; M801H13NRU / Azacitidine
  •  go-up   go-down


33. Mustur D, Vesović-Potić V, Ille T, Stanisavljević D, Ille M: [Assessment of health-related quality of life of patients with chronic arthritis]. Srp Arh Celok Lek; 2009 Nov-Dec;137(11-12):684-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assessment of health-related quality of life of patients with chronic arthritis].
  • The assessment of the quality of life as a subjective measure of therapeutic intervention outcome appears to be increasingly adopted by different fields of medicine.
  • Chronic arthritis leads to irreversible structural changes in joints and consequently to impaired physical function and reduced HRQoL.
  • Today there are validated disease specific ("target") questionnaires to assess HRQoL in patients with rheumatoid arthritis and ankylosing spondylitis, but not yet in patients with psoriatic arthritis.
  • A disease specific questionnaire makes easier approach to patients suffering from a specific rheumatic condition; it enables the comparison of HRQoL among patients suffering from the different types of chronic arthritis.
  • The most frequently used questionnaire in the assessment of the HRQoL of patients suffering from chronic arthritis is the generic MOS 36-Item Short-Form Health Survey (SF-36) which is considered as the "gold standard".
  • It is a generic questionnaire for the assessment of HRQoL in patients with chronic arthritis.
  • To our knowledge, there are only a few studies focused on the HRQoL of patients suffering from chronic arthritis in Serbia and Montenegro.
  • [MeSH-minor] Chronic Disease. Health Status. Humans. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20069930.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Serbia
  • [Number-of-references] 39
  •  go-up   go-down


34. Pinheiro de Melo EM, Lopes Ferreira P: [Quality of life 2 years after coronary revascularization]. Enferm Clin; 2007 Nov-Dec;17(6):309-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Calidad de vida 2 años después de la revascularización coronaria.
  • OBJECTIVE: To determine the impact of coronary revascularization surgery on patients' quality of life and to identify the presence of lifestyles representing a risk for coronary heart disease.
  • As measurement instruments, the MOS Health Survey (SF-36), the Nottingham Health Profile (NHP) and a questionnaire to identify lifestyles were used.
  • Before surgery, significant physical limitations were present in 39.5%, comorbidity in 79%, prior infarction in 8.7% and three-vessel disease in 68%.
  • [MeSH-minor] Adult. Aged. Coronary Disease / epidemiology. Coronary Disease / etiology. Female. Humans. Life Style. Male. Middle Aged. Prospective Studies. Risk Factors. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039439.001).
  • [ISSN] 1130-8621
  • [Journal-full-title] Enfermería clínica
  • [ISO-abbreviation] Enferm Clin
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


35. Hasson E, Gallula J, Shimoni Y, Grad-Itach E, Marikovsky M, Mitrani E: Skin-derived micro-organs induce angiogenesis in rabbits. J Vasc Res; 2006;43(2):139-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The approach is based on small organ fragments--micro-organs (MOs)--whose geometry allows preservation of the natural epithelial/mesenchymal interactions and ensures appropriate diffusion of nutrients and gases to all cells.
  • We have shown that lung-derived MOs, when implanted into hosts, transcribe a wide spectrum array of angiogenic factors and can induce an angiogenic response that can rescue experimentally induced ischemic regions in mice.
  • From a clinical perspective, skin-derived MOs are particularly appealing as they could readily be obtained from a skin biopsy taken from the same target patient.
  • Rabbit skin MOs were implanted into homologous adult rabbits and human skin MOs were encapsulated and implanted into xenogenic mice.
  • Skin-derived MOs, as lung-derived MOs, were found to secrete a whole array of angiogenic factors and to induce a powerful angiogenic response when implanted back into animals.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16407659.001).
  • [ISSN] 1018-1172
  • [Journal-full-title] Journal of vascular research
  • [ISO-abbreviation] J. Vasc. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


36. Zhu FF, Lin Z, Lin L, Wang MF, Zhou LR: [The effects of biofeedback training on clinical symptoms, psychological status and quality of life in patients with functional constipation]. Zhonghua Nei Ke Za Zhi; 2010 Jul;49(7):591-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bowel symptom measure, Zung's self-rating anxiety scale (SAS), self-rating depression scale (SDS) and Chinese version of the MOS 36-item short form healthy survey (SF-36) were recorded to assess the effects before and after treatment.
  • RESULTS: After biofeedback training, clinical symptom of patients with FC was greatly improved: there was a very significant decrease in total and subscales scores of bowel symptom including spontaneous frequency of bowel movements, straining effort, sensation of anorectal obstruction/blockage, stool consistency and bloating.

  • Genetic Alliance. consumer health - Constipation.
  • MedlinePlus Health Information. consumer health - Constipation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979770.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


37. Vannucchi AM, Guglielmelli P: Advances in understanding and management of polycythemia vera. Curr Opin Oncol; 2010 Nov;22(6):636-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Polycythemia vera is a relatively common myeloproliferative neoplasm (MPN) molecularly defined by the presence of mutations in the janus kinase (JAK2) gene.
  • Yet, many aspects of pathogenesis remain to be ascertained and no effective treatment for curing the disease or preventing major cardiovascular events and progression to myelofibrosis or acute leukemia exists.
  • RECENT FINDINGS: The discovery of a specific germline haplotype in JAK2 provided an explanation for the well known phenomenon of familial clustering of MPN.
  • However, the expectation that these drugs could selectively target mutant cells and cause a molecular remission, similar to the experience with imatinib in chronic myelogenous leukemia, has been largely unmet.

  • Genetic Alliance. consumer health - Polycythemia vera.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20805747.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


38. Turner RT, Iwaniec UT, Marley K, Sibonga JD: The role of mast cells in parathyroid bone disease. J Bone Miner Res; 2010 Jul;25(7):1637-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of mast cells in parathyroid bone disease.
  • Chronic hyperparathyroidism (HPT) is a common cause of metabolic bone disease.
  • Bone biopsies from hyperparathyroid patients revealed an association between parathyroid bone disease and increased numbers of bone marrow mast cells.
  • We therefore evaluated the role of mast cells in the etiology of parathyroid bone disease in a rat model for chronic HPT.
  • In rats, mature mast cells were preferentially located at sites undergoing bone turnover, and the number of mast cells at the bone-bone marrow interface was greatly increased following treatment with PTH.
  • Time-course studies and studies employing parathyroid hormone-related peptide (PTHrP), as well as inhibitors of platelet-derived growth factor-A (PDGF-A, trapidil), kit (gleevec), and PI3K (wortmannin) signaling revealed that mature mast cell redistribution from bone marrow to bone surfaces precedes and is associated with osteitis fibrosa, a hallmark of parathyroid bone disease.
  • Importantly, mature mast cells were not observed in the bone marrow of mice.
  • Mice, in turn, were resistant to the development of PTH-induced bone marrow fibrosis.
  • These findings suggest that the mast cell may be a novel target for treatment of metabolic bone disease.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 American Society for Bone and Mineral Research.
  • [Cites] Nat Genet. 2000 Mar;24(3):304-8 [10700189.001]
  • [Cites] Nephron. 2000 Mar;84(3):224-7 [10720892.001]
  • [Cites] Med Hypotheses. 2000 Feb;54(2):236-8 [10790758.001]
  • [Cites] Bone. 2000 Aug;27(2):209-18 [10913913.001]
  • [Cites] Kidney Int Suppl. 2001 Feb;78:S186-9 [11169008.001]
  • [Cites] Bone. 2002 Jan;30(1):131-6 [11792575.001]
  • [Cites] Blood. 2002 May 1;99(9):3342-9 [11964302.001]
  • [Cites] Surgery. 2002 Dec;132(6):1075-83; discussion 1083-5 [12490858.001]
  • [Cites] Endocrinology. 2003 May;144(5):2000-7 [12697708.001]
  • [Cites] Bone. 2003 May;32(5):513-20 [12753867.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2003 Jul;12(4):387-403 [12815335.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):841-6 [14574413.001]
  • [Cites] J Bone Miner Res. 2003 Dec;18(12):2190-9 [14672354.001]
  • [Cites] Bone. 2004 Jan;34(1):91-9 [14751566.001]
  • [Cites] Exp Physiol. 2006 May;91(3):561-70 [16513821.001]
  • [Cites] J Am Acad Orthop Surg. 2006 May;14(5):303-11 [16675624.001]
  • [Cites] Nat Med. 2006 Jun;12(6):657-64 [16715089.001]
  • [Cites] Bone. 2006 Aug;39(2):260-7 [16531131.001]
  • [Cites] J Appl Physiol (1985). 2006 Sep;101(3):881-6 [16675609.001]
  • [Cites] J Bone Miner Res. 2007 Mar;22(3):394-402 [17147489.001]
  • [Cites] J Bone Miner Res. 2007 Apr;22(4):495-502 [17227219.001]
  • [Cites] Blood. 2007 May 1;109(9):3679-86 [17213284.001]
  • [Cites] Bone. 2007 Jun;40(6):1434-46 [17517365.001]
  • [Cites] J Am Soc Nephrol. 2007 Aug;18(8):2401-7 [17634437.001]
  • [Cites] J Bone Miner Res. 2007 Nov;22(11):1679-89 [17663639.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1670-5 [17911347.001]
  • [Cites] Methods Mol Biol. 2008;447:325-41 [18369927.001]
  • [Cites] Bone. 2008 Jun;42(6):1025-31 [18396127.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Jul;69(1):1-19 [18167138.001]
  • [Cites] Kidney Int. 2008 Aug;74(3):319-27 [18463610.001]
  • [Cites] Endocrinology. 2008 Nov;149(11):5735-46 [18635661.001]
  • [Cites] Am J Pathol. 2009 Apr;174(4):1426-34 [19264900.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 2004 Mar;112(3):127-30 [15052531.001]
  • [Cites] Curr Pharm Des. 2004;10(21):2615-27 [15320749.001]
  • [Cites] J Clin Pathol. 1976 Jun;29(6):502-16 [939806.001]
  • [Cites] J Clin Pathol. 1977 Oct;30(10):960-5 [338636.001]
  • [Cites] Biochem Pharmacol. 1983 Jan 15;32(2):355-60 [6191761.001]
  • [Cites] Proc Soc Exp Biol Med. 1985 Dec;180(3):544-9 [4080703.001]
  • [Cites] J Submicrosc Cytol. 1986 Jan;18(1):221-4 [2421011.001]
  • [Cites] J Clin Invest. 1990 Jun;85(6):2023-7 [2347924.001]
  • [Cites] Am J Hematol. 1990 Nov;35(3):145-50 [2220756.001]
  • [Cites] Endocrinology. 1992 Jul;131(1):5-13 [1319327.001]
  • [Cites] Semin Nephrol. 1993 Jan;13(1):87-95 [8434190.001]
  • [Cites] Br J Haematol. 1994 Feb;86(2):303-7 [8199019.001]
  • [Cites] J Immunol. 1994 Sep 15;153(6):2819-30 [7521370.001]
  • [Cites] Gastroenterology. 1995 Jan;108(1):145-56 [7806036.001]
  • [Cites] Endocrinology. 1995 Aug;136(8):3632-8 [7628403.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Apr;277(1):543-50 [8613966.001]
  • [Cites] Life Sci. 1996;58(21):1861-8 [8637412.001]
  • [Cites] Am J Kidney Dis. 1996 Dec;28(6):918-23 [8957047.001]
  • [Cites] Endocrinology. 1997 Nov;138(11):4607-12 [9348185.001]
  • [Cites] Blood Rev. 1997 Dec;11(4):233-42 [9481452.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):718-22 [10022443.001]
  • [Cites] Osaka City Med J. 1998 Dec;44(2):133-53 [10097595.001]
  • [Cites] Virchows Arch. 1999 Jul;435(1):50-7 [10431846.001]
  • [Cites] BMC Gastroenterol. 2004 Dec 3;4:30 [15579200.001]
  • [Cites] J Exp Med. 2005 Mar 21;201(6):925-35 [15781583.001]
  • [Cites] J Cell Biochem. 2005 May 15;95(2):403-18 [15779007.001]
  • [Cites] Clin Nephrol. 2005 Apr;63(4):284-9 [15847255.001]
  • [Cites] Endocrinology. 2005 Sep;146(9):4074-81 [15947001.001]
  • [Cites] Bone. 2006 Jan;38(1):59-66 [16249129.001]
  • (PMID = 20200965.001).
  • [ISSN] 1523-4681
  • [Journal-full-title] Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • [ISO-abbreviation] J. Bone Miner. Res.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR048833-03; United States / NIAMS NIH HHS / AR / R01 AR048833; United States / NIAMS NIH HHS / AR / AR48833; United States / NIAMS NIH HHS / AR / R01 AR048833-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androstadienes; 0 / Benzamides; 0 / Parathyroid Hormone; 0 / Parathyroid Hormone-Related Protein; 0 / Piperazines; 0 / Platelet-Derived Growth Factor; 0 / Pyrimidines; 0 / platelet-derived growth factor A; 8A1O1M485B / Imatinib Mesylate; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EYG5Y6355E / Trapidil; XVA4O219QW / wortmannin
  • [Other-IDs] NLM/ PMC3154003
  •  go-up   go-down


39. Shalit P, True A, Thommes JA, QUALITE Investigators: Quality of life and tolerability after administration of enfuvirtide with a thin-walled needle: QUALITE Study. HIV Clin Trials; 2007 Jan-Feb;8(1):24-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life and tolerability after administration of enfuvirtide with a thin-walled needle: QUALITE Study.
  • Patients self-administered enfuvirtide, 90 mg bid, using thin-walled, 31-gauge/8-mm needles in combination with other ARvs. QoL was evaluated with MOS-HIV.
  • Although no baseline factors were predictive of week 12 QoL improvement, 9 of 11 MOS-HIV domain scores improved significantly, including physical function (p = .0002) and mental health (p = .0006).

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434846.001).
  • [ISSN] 1528-4336
  • [Journal-full-title] HIV clinical trials
  • [ISO-abbreviation] HIV Clin Trials
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / HIV Envelope Protein gp41; 0 / HIV Fusion Inhibitors; 0 / Peptide Fragments; 19OWO1T3ZE / enfuvirtide
  •  go-up   go-down


40. Guglielmelli P, Barosi G, Specchia G, Rambaldi A, Lo Coco F, Antonioli E, Pieri L, Pancrazzi A, Ponziani V, Delaini F, Longo G, Ammatuna E, Liso V, Bosi A, Barbui T, Vannucchi AM: Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood; 2009 Aug 20;114(8):1477-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.
  • A total of 186 patients with primary myelofibrosis (PMF) were genotyped for JAK2V617F at diagnosis aimed at analyzing the correlation of mutational status and mutated allele burden with outcome variables, including time to anemia, leukocytosis, leukopenia, thrombocytopenia, massive splenomegaly, leukemia, and with overall survival.
  • In multivariate analysis, factors associated with reduced survival were age, a blast count more than 1%, and a JAK2V617F burden within first quartile.
  • We conclude that a low JAK2V617F allele burden at diagnosis is preferentially associated with a myelodepletive rather than myeloproliferative phenotype and represents an independent factor associated with shortened survival in patients with PMF.
  • [MeSH-major] Janus Kinase 2 / genetics. Primary Myelofibrosis / genetics. Primary Myelofibrosis / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Alleles. Amino Acid Substitution / genetics. DNA Mutational Analysis. Female. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Mutation, Missense. Phenylalanine / genetics. Prognosis. Survival Analysis. Valine / genetics. Young Adult

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • Hazardous Substances Data Bank. L-Valine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549988.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 47E5O17Y3R / Phenylalanine; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; HG18B9YRS7 / Valine
  •  go-up   go-down


41. Russo GL, Bilotto S, Ciarcia G, Tosti E: Phylogenetic conservation of cytostatic factor related genes in the ascidian Ciona intestinalis. Gene; 2009 Jan 15;429(1-2):104-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, we proposed the oocytes of ascidian Ciona intestinalis as a new model to study the meiotic division.
  • We showed that the Mos/MAP kinase pathway is perfectly conserved in ascidians.
  • We demonstrated the presence of a CSF-like activity in metaphase-I arrested C. intestinalis oocytes able to block cell division in two-cell embryos.
  • [MeSH-major] Ciona intestinalis / genetics. Conserved Sequence. Phylogeny. Proto-Oncogene Proteins c-mos / genetics

  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18977421.001).
  • [ISSN] 1879-0038
  • [Journal-full-title] Gene
  • [ISO-abbreviation] Gene
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.11.1 / Proto-Oncogene Proteins c-mos
  •  go-up   go-down


42. Akagawa KS, Komuro I, Kanazawa H, Yamazaki T, Mochida K, Kishi F: Functional heterogeneity of colony-stimulating factor-induced human monocyte-derived macrophages. Respirology; 2006 Jan;11 Suppl:S32-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODOLOGY: CD14 positive human monocytes (Mos) were incubated with M-CSF and GM-CSF for 6-7 days to stimulate the generation of M-CSF-induced monocyte-derived Mphis (M-Mphis) and GM-CSF-induced monocyte-derived Mphis (GM-Mphis), respectively.
  • RESULTS: GM-Mphis and M-Mphis are distinct in their morphology, cell surface antigen expression, and functions examined.
  • [MeSH-minor] Catalase / metabolism. Cells, Cultured. Disease Susceptibility / immunology. HIV Infections / immunology. HIV-1 / growth & development. Humans. Interferon-gamma / metabolism. Interleukin-10 / metabolism. Mycobacterium tuberculosis / growth & development. Phagocytosis / physiology. Phenotype. Recombinant Proteins. T-Lymphocytes / metabolism. Tuberculosis / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16423268.001).
  • [ISSN] 1323-7799
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Recombinant Proteins; 130068-27-8 / Interleukin-10; 81627-83-0 / Macrophage Colony-Stimulating Factor; 82115-62-6 / Interferon-gamma; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; EC 1.11.1.6 / Catalase
  •  go-up   go-down


43. Jakobsen HJ, Hove AR, Bildsøe H, Skibsted J, Brorson M: Advancements in natural abundance solid-state 33S MAS NMR: characterization of transition-metal M=S bonds in ammonium tetrathiometallates. Chem Commun (Camb); 2007 Apr 28;(16):1629-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advancements in natural abundance solid-state 33S MAS NMR: characterization of transition-metal M=S bonds in ammonium tetrathiometallates.
  • We report the first (33)S chemical shift anisotropy (CSA) data as obtained from a combined determination of (33)S CSA and quadrupole coupling parameters utilizing the observation of both the (33)S (I = 3/2) central and satellite transitions in a natural abundance (33)S MAS NMR study aimed at characterizing the two important tetrathiometallates (NH4)(2)MoS(4) and (NH4)(2)WS(4).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17530082.001).
  • [ISSN] 1359-7345
  • [Journal-full-title] Chemical communications (Cambridge, England)
  • [ISO-abbreviation] Chem. Commun. (Camb.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


44. Sato K, Shibata H, Mizuguchi J: Poly[tris{μ(2)-4-[4-(di-methyl-amino)-phenyl-diazenyl]benzene-sulfonato}tri-dioxane-tri-sodium(I)]. Acta Crystallogr Sect E Struct Rep Online; 2008;64(Pt 4):m586-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One of the seven-coordinate centres is coordinated by six O atoms from the sulfonate groups of four different MOs and by one O atom from dioxane.
  • The other is coordinated by seven O atoms from the sulfonate groups of five different MOs.
  • The five-coordinate centre is coordinated by three O atoms from the sulfonate groups of three different MOs and two O atoms from two different dioxanes.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22 [18156677.001]
  • [Cites] Chemistry. 2004 Sep 20;10(18):4606-15 [15378640.001]
  • (PMID = 21202034.001).
  • [ISSN] 1600-5368
  • [Journal-full-title] Acta crystallographica. Section E, Structure reports online
  • [ISO-abbreviation] Acta Crystallogr Sect E Struct Rep Online
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2961004
  •  go-up   go-down


45. Hamid GA, Shukry SA: Patterns of pancytopenia in Yemen. Turk J Haematol; 2008 Jun 5;25(2):71-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Yemen'de pansitopeni nedenleri.
  • The other causes as determined in the present study were myelodysplasia in 8.0%, myelofibrosis in 4.0% and iron deficiency anemia in 1.3%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27264442.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


46. Groll DL, Heyland DK, Caeser M, Wright JG: Assessment of long-term physical function in acute respiratory distress syndrome (ARDS) patients: comparison of the Charlson Comorbidity Index and the Functional Comorbidity Index. Am J Phys Med Rehabil; 2006 Jul;85(7):574-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 73 survivors of acute respiratory distress syndrome were contacted at 3, 6, and 12 mos.
  • RESULT: Mean FCI and Charlson Comorbidity Index scores correlated fairly strongly (Spearman rho = 0.62, P < 0.001).

  • Genetic Alliance. consumer health - Acute Respiratory Distress Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16788388.001).
  • [ISSN] 0894-9115
  • [Journal-full-title] American journal of physical medicine & rehabilitation
  • [ISO-abbreviation] Am J Phys Med Rehabil
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Tan YQ, Di YF, Song YZ, Cheng DH, Li LY, Lu GX: [Delineating a supernumerary marker chromosome by combining several cytogenetic and molecular cytogenetic techniques]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug;24(4):392-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To characterize a supernumerary marker chromosome (SMC) by comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH) and traditional cytogenetic techniques, and to explore the clinical application of these techniques in delineating de novo marker chromosomes.
  • CGH and FISH techniques were used to analyze the origin of the de novo SMC, and N banding technique and C banding techniques were used to analyze the SMC structure.
  • RESULTS: By G banding technique, the patient was showed to have a mosaic karyotype with SMC: mos.47, XX, +mar [31]/48, XX, +2mar[29].
  • CGH analysis showed a gain of 15q11 --> q14, and the result was confirmed by FISH with chromosome 15 painting probe.
  • Combined with the above results, the karyotype of the patient was: mos.47, XX, +der (15) (pter --> q14::q14 --> pter) [31]/48, XX, +2der (15) (pter --> q14::q14 --> pter) [29].
  • Combined with FISH and the traditional cytogenetic technique, it provides a valuable technique platform for characterizing the structure of the de novo SMC, and a basis for exploring the relation between karyotype and phenotype, prognosis and recurrent risk.
  • [MeSH-minor] Chromosome Banding. Comparative Genomic Hybridization. Female. Humans. In Situ Hybridization, Fluorescence. Infant. Intellectual Disability / diagnosis. Intellectual Disability / genetics. Karyotyping

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17680527.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


48. González-Viejo MA, Avellanet M, Hernández-Morcuende MI: [A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment]. Ann Readapt Med Phys; 2005 Nov;48(8):610-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Etude comparative dans traitement de la fibromyalgie: ultrasons et kinésithérapie versus sertraline.
  • Variables analyzed on a visual 10-point scale were pain and morning stiffness and sleep disorders by use of the sleep questionnaire of the Medical Outcome Study (MOS).
  • Morning stiffness and sleep disorder scores were positive only for the sertraline group during the entire 6 months (P<0.05).
  • Results from the MOS questionnaire showed improvement only for the sertraline group.

  • Genetic Alliance. consumer health - Fibromyalgia.
  • MedlinePlus Health Information. consumer health - Fibromyalgia.
  • Hazardous Substances Data Bank. SERTRALINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15979192.001).
  • [ISSN] 0168-6054
  • [Journal-full-title] Annales de réadaptation et de médecine physique : revue scientifique de la Société française de rééducation fonctionnelle de réadaptation et de médecine physique
  • [ISO-abbreviation] Ann Readapt Med Phys
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Serotonin Uptake Inhibitors; QUC7NX6WMB / Sertraline
  •  go-up   go-down


49. Liu AN, Chen HS, Liu EB, Fang LH, Yang QY, Qian LS: [Study of 161 chronic idiopathic myelofibrosis patients for clinicopathological staging]. Zhonghua Xue Ye Xue Za Zhi; 2006 Mar;27(3):178-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of 161 chronic idiopathic myelofibrosis patients for clinicopathological staging].
  • OBJECTIVE: To investigate the significance of clinicopathological stage of chronic idiopathic myelofibrosis (CIMF) in WHO classification of 2001.
  • METHODS: Histopathological analysis of bone marrow biopsy plastic-embedded sections stained with H-G-E and Gomori's stains and clinical features of 113 cases previously diagnosed as primary myelofibrosis (PMF) and 48 cases MPD-U (total of 161 cases which including male 79 and female 82) were studied retrospectively.
  • According to WHO classification 2001 of CIMF, previously diagnosis in 48 cases with MPD-U was WHO pre-CIMF, and in 113 cases with PMF was WHO CIMF-Fs.
  • There were significant differences between of WHO pre-CIMF and WHO CIMF-Fs about clinicopathological features except age.
  • The percentage of immature granulocytes, normoblasts, lymphocytes in peripheral blood, the size of hepatosplenomegaly, and the percent age of tear drop-like red blood cells in pre-CIMF were significantly lower than those in CIMF-Fs (P < 0.05).
  • However, the number of hemoglobin and platelets in patients with pre-CIMF were significantly higher than that with CIMF-Fs (P < 0.01).
  • CONCLUSION: pre-CIMF and CIMF-Fs in clinical and histopathological features were different development stage of CIMF, while osteomyelosclerosis is a variant of CIMF, but not an independent disease.
  • [MeSH-major] Bone Marrow / pathology. Primary Myelofibrosis / pathology
  • [MeSH-minor] Adult. Aged. Biopsy. Chronic Disease. Female. Humans. Male. Middle Aged. Thrombopoiesis

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16792920.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


50. Kovac IP, Dubé MP: Different models and single-nucleotide polymorphisms signal the simulated weak gene-gene interaction for a quantitative trait using haplotype-based and mixed models testing. BMC Proc; 2009;3 Suppl 7:S77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using the 200 replicates of the Genetic Analysis Workshop 16 (GAW16) Problem 3 simulated data, we compared the statistical power to detect weak gene-gene interactions using a haplotype-based test in the UNPHASED software with genotypic mixed model (GMM) and additive mixed model (AMM) mixed linear regression model in SAS.
  • Over all tests, the haplotype-based test performed within chance, while GMM and AMM had low power (~10%).
  • The haplotype-based test detected a signal in 50 unique replicates; GMM and AMM featured both shared and distinct SNPs and replicates (65 replicates shared, 41 GMM, 27 AMM).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Hum Hered. 2008;66(2):87-98 [18382088.001]
  • [Cites] Hum Hered. 2007;63(2):67-84 [17283436.001]
  • (PMID = 20018072.001).
  • [ISSN] 1753-6561
  • [Journal-full-title] BMC proceedings
  • [ISO-abbreviation] BMC Proc
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM031575; United States / NIGMS NIH HHS / GM / R01 GM031575-28
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2795979
  •  go-up   go-down


51. Fitzpatrick EM, Durieux-Smith A, Whittingham J: Clinical practice for children with mild bilateral and unilateral hearing loss. Ear Hear; 2010 Jun;31(3):392-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: This population-based study consisted of a detailed retrospective chart review of all children identified with mild bilateral or unilateral hearing loss in a Canadian pediatric center between 1990 and 2006.
  • Clinical decisions regarding amplification practices were explored as a function of age of identification and severity of hearing loss.
  • RESULTS: A total of 670 children were identified with permanent hearing loss during the 16-yr study period, of which 291 were presented with a mild bilateral or unilateral hearing loss.
  • Detailed reviews of the 255 available medical charts showed that at diagnosis, 178 children presented with mild bilateral, 31 with mild bilateral high frequency, and 46 with unilateral hearing loss.
  • The average age of identification for the entire group was 54.2 mos (interquartile range, 30.1 to 76.9 mos).
  • Overall, 54.1% received an initial recommendation for amplification and a further 37.3% received a recommendation more than 3 mos after hearing loss confirmation.

  • MedlinePlus Health Information. consumer health - Hearing Aids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20054278.001).
  • [ISSN] 1538-4667
  • [Journal-full-title] Ear and hearing
  • [ISO-abbreviation] Ear Hear
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


52. Jałocha I, Gabryś MS, Bal J: [The crucial role of the proto-oncogene c-mos in regulation of oocyte maturation]. Postepy Hig Med Dosw (Online); 2010 Dec 02;64:636-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The crucial role of the proto-oncogene c-mos in regulation of oocyte maturation].
  • [Transliterated title] Rola protoonkogenu c-mos w regulacji procesu dojrzewania komórki jajowej.
  • The c-mos proto-oncogene, which is specifically expressed in female and male germ cells, plays a crucial role in control of meiotic cell division in mammals.
  • Its product--Mos protein kinase--acting through mitogen-activated protein kinases (MAPKs) regulates critical cellular functions required for homeostasis and decides about cell survival or apoptosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160098.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] EC 2.7.11.1 / Proto-Oncogene Proteins c-mos; EC 2.7.11.22 / Maturation-Promoting Factor; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


53. Kuter DJ, Mufti GJ, Bain BJ, Hasserjian RP, Davis W, Rutstein M: Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood; 2009 Oct 29;114(18):3748-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.
  • Romiplostim is a thrombopoietin receptor agonist that increases platelet counts in patients with chronic immune thrombocytopenia (ITP).
  • Thrombopoietin receptor agonists are reported to increase the risk for reticulin fiber deposition within bone marrow.
  • This report describes bone marrow findings from romiplostim-treated rats, a retrospective analysis of reticulin observed in romiplostim ITP clinical trials, and a prospective clinical study of the effects of romiplostim on bone marrow morphology.
  • In rats, romiplostim produced a dose-dependent increase in bone marrow fibrosis that resolved after treatment withdrawal.
  • Of 271 ITP patients in romiplostim clinical trials, 10 were reported to have reticulin deposition; reticulin grade was increased in 4 of 5 patients with both pretreatment and on-treatment bone marrow results.
  • In the prospective study, reticulin grade during romiplostim treatment remained within the normal range for all patients and was increased in only 1 of 6 patients with pretreatment and on-treatment bone marrow results.
  • This report suggests that romiplostim produces reversible, dose-dependent bone marrow changes in rats and produces modest increases in bone marrow reticulin in some ITP patients that decrease when therapy is discontinued.
  • [MeSH-major] Bone Marrow / metabolism. Carrier Proteins / administration & dosage. Purpura, Thrombocytopenic, Idiopathic / drug therapy. Purpura, Thrombocytopenic, Idiopathic / metabolism. Receptors, Fc / administration & dosage. Reticulin / metabolism

  • Genetic Alliance. consumer health - Immune thrombocytopenia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2009 Oct 29;114(18):3722-3 [19875521.001]
  • (PMID = 19671919.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00102323/ NCT00102336/ NCT00116688/ NCT00861224
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Receptors, Fc; 0 / Receptors, Thrombopoietin; 0 / Recombinant Fusion Proteins; 0 / Reticulin; 0 / romiplostim; 9014-42-0 / Thrombopoietin
  •  go-up   go-down


54. Jacquot BC, Muñoz N, Branch DW, Kan EC: Non-Faradaic electrochemical detection of protein interactions by integrated neuromorphic CMOS sensors. Biosens Bioelectron; 2008 May 15;23(10):1503-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Faradaic electrochemical detection of protein interactions by integrated neuromorphic CMOS sensors.
  • Electronic detection of the binding event between biotinylated bovine serum albumen (BSA) and streptavidin is demonstrated with the chemoreceptive neuron MOS (CnuMOS) device.
  • In comparison with the microelectrode arrays, measurements are gathered through purely capacitive, non-Faradaic interactions across insulating interfaces.
  • By using a (3-glycidoxypropyl)trimethoxysilane (3-GPS) self-assembled monolayer (SAM) as a simple covalent link for attaching proteins to a silicon dioxide sensing surface, a fully integrated, electrochemical detection platform is realized for protein interactions through monotone large-signal measurements or small-signal impedance spectroscopy.
  • Calibration curves were created to coordinate the sensor response with ellipsometric measurements taken on witness samples.
  • With an improved noise floor the sensor can detect down to 2ng/(cm2mV) based on the calibration curve.
  • AC measurements are shown to significantly reduce long-term sensor drift.
  • Finally, a noise analysis of electrochemical data indicates 1/f(alpha) behavior with a noise floor beginning at approximately 1Hz.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281208.001).
  • [ISSN] 0956-5663
  • [Journal-full-title] Biosensors & bioelectronics
  • [ISO-abbreviation] Biosens Bioelectron
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  •  go-up   go-down


55. Percy MJ, McMullin MF: The V617F JAK2 mutation and the myeloproliferative disorders. Hematol Oncol; 2005 Sep-Dec;23(3-4):91-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The V617F JAK2 mutation and the myeloproliferative disorders.
  • The discovery this year of a single mutation in the Janus Kinase (JAK)-2 gene in a high percentage of cases of polycythaemia vera (PV), essential thrombocythaemia (ET) and myelofibrosis suggests that it maybe the underlying molecular mechanism for these disorders.
  • Substitution of a valine for a phenylalanine destabilizes the JH2 domain of JAK2 causes loss of the auto-inhibitory activity of this domain and explains some of the biological phenomena observed in patients with myeloproliferative disorders (MPD).
  • This leads to a number of further questions about the role of this single mutation in the clinical pattern of disease.
  • [MeSH-major] Alleles. Amino Acid Substitution. Chromosomes, Human, Pair 9 / genetics. Myeloproliferative Disorders / genetics. Point Mutation. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins / genetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • Hazardous Substances Data Bank. L-Valine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 John Wiley & Sons, Ltd.
  • (PMID = 16285006.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 47E5O17Y3R / Phenylalanine; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; HG18B9YRS7 / Valine
  • [Number-of-references] 19
  •  go-up   go-down


56. Torén K, Bergdahl IA, Nilsson T, Järvholm B: Occupational exposure to particulate air pollution and mortality due to ischaemic heart disease and cerebrovascular disease. Occup Environ Med; 2007 Aug;64(8):515-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational exposure to particulate air pollution and mortality due to ischaemic heart disease and cerebrovascular disease.
  • OBJECTIVES: A growing number of epidemiological studies are showing that ambient exposure to particulate matter air pollution is a risk factor for cardiovascular disease; however, whether occupational exposure increases this risk is not clear.
  • The aim of the present study was to examine whether occupational exposure to particulate air pollution increases the risk for ischaemic heart disease and cerebrovascular disease.
  • The definition of exposure to inorganic dust (asbestos, man-made mineral fibres, dust from cement, concrete and quartz), wood dust, fumes (metal fumes, asphalt fumes and diesel exhaust) and gases and irritants (organic solvents and reactive chemicals) was based on a job-exposure matrix with focus on exposure in the mid-1970s.
  • The cohort was followed from 1971 to 2002 with regard to mortality to ischaemic heart disease and cerebrovascular disease.
  • RESULTS: Any occupational particulate air pollution was associated with an increased risk for ischemic heart disease (RR 1.13, 95% CI 1.07 to 1.19), but there was no increased risk for cerebrovascular disease (RR 0.97, 95% CI 0.88 to 1.07).
  • There was an increased risk for ischaemic heart disease and exposure to inorganic dust (RR 1.07, 95% CI 1.03 to 1.12) and exposure to fumes (RR 1.05, 95% CI 1.00 to 1.10), especially diesel exhaust (RR 1.18, 95% CI 1.13 to 1.24).
  • There was no significantly increased risk for cerebrovascular disease and exposure to inorganic dust, fumes or wood dust.
  • CONCLUSIONS: Occupational exposure to particulate air pollution, especially diesel exhaust, among construction workers increases the risk for ischaemic heart disease.

  • Genetic Alliance. consumer health - Heart Disease.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Circulation. 2000 Mar 21;101(11):1267-73 [10725286.001]
  • [Cites] Occup Environ Med. 1999 Sep;56(9):612-7 [10615294.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1742-9 [11114312.001]
  • [Cites] Epidemiology. 2001 Mar;12(2):222-8 [11246584.001]
  • [Cites] Epidemiology. 2001 May;12(3):355-7 [11337606.001]
  • [Cites] Circulation. 2001 Aug 28;104(9):986-91 [11524390.001]
  • [Cites] Occup Environ Med. 2002 Jan;59(1):9-12 [11836462.001]
  • [Cites] JAMA. 2002 Mar 6;287(9):1132-41 [11879110.001]
  • [Cites] Circulation. 2002 Aug 20;106(8):933-8 [12186796.001]
  • [Cites] Stroke. 2002 Sep;33(9):2165-9 [12215581.001]
  • [Cites] Circulation. 2003 Mar 4;107(8):1202-8 [12615802.001]
  • [Cites] Circulation. 2004 Jan 6;109(1):71-7 [14676145.001]
  • [Cites] Eur Respir J. 2004 Mar;23(3):402-6 [15065829.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Apr 15;169(8):934-40 [14962820.001]
  • [Cites] Am J Epidemiol. 1983 Feb;117(2):160-4 [6829545.001]
  • [Cites] Biometrics. 1983 Mar;39(1):173-84 [6871346.001]
  • [Cites] Br J Ind Med. 1986 Oct;43(10):677-84 [3778838.001]
  • [Cites] Scand J Work Environ Health. 1992 Jun;18(3):178-85 [1615292.001]
  • [Cites] N Engl J Med. 1993 Dec 9;329(24):1753-9 [8179653.001]
  • [Cites] Am J Respir Crit Care Med. 1995 Mar;151(3 Pt 1):669-74 [7881654.001]
  • [Cites] Lancet. 1996 Aug 31;348(9027):567-72 [8774568.001]
  • [Cites] Environ Health Perspect. 1999 Jul;107(7):521-5 [10378998.001]
  • [Cites] Thorax. 1999 Nov;54(11):1027-32 [10525563.001]
  • [Cites] Scand J Work Environ Health. 2004 Dec;30(6):421-3 [15633592.001]
  • [Cites] Stroke. 2005 Feb;36(2):239-43 [15604422.001]
  • [Cites] Thorax. 2005 Jun;60(6):441-2 [15923240.001]
  • [Cites] Circulation. 2005 Dec 20;112(25):3930-6 [16365212.001]
  • [Cites] Am J Respir Crit Care Med. 2006 Mar 15;173(6):667-72 [16424447.001]
  • [Cites] Circ Res. 2006 Sep 29;99(7):692-705 [17008598.001]
  • [Cites] Am Heart J. 1999 Nov;138(5 Pt 1):804-7 [10539808.001]
  • [Cites] Am Heart J. 1999 Nov;138(5 Pt 1):890-9 [10539820.001]
  • [Cites] Epidemiology. 2000 Jan;11(1):11-7 [10615837.001]
  • [Cites] N Engl J Med. 2000 Nov 2;343(18):1305-11 [11058675.001]
  • (PMID = 17303673.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Dust; 0 / Gases; 0 / Particulate Matter
  • [Other-IDs] NLM/ PMC2078490
  •  go-up   go-down


57. Liu P, Choi Y, Yang Y, White MG: Methanol synthesis from H2 and CO2 on a Mo6S8 cluster: a density functional study. J Phys Chem A; 2010 Mar 25;114(11):3888-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our calculations indicate that the preferred catalytic pathway for methanol synthesis on the Mo(6)S(8) cluster is very different from that of bulklike MoS(2).
  • MoS(2) promotes the C-O scission of H(x)CO intermediates, and therefore, only hydrocarbons are produced.
  • The lower S/Mo ratio for the cluster compared to stoichiometric MoS(2) might be expected to lead to higher activity because more low-coordinated Mo sites are available for reaction.
  • However, our results show that the Mo(6)S(8) cluster is not as reactive as bulk MoS(2) because it is unable to break the C-O bond of H(x)CO intermediates and therefore cannot produce hydrocarbons.
  • The rate-limiting step is CO hydrogenation to the HCO with a calculated barrier of +1 eV.
  • This barrier is much lower than that calculated for a comparably sized Cu nanoparticle, which is the prototypical metal catalyst used for methanol synthesis from syngas (CO + H(2)).
  • Our study reveals that the unexpected activity of the Mo(6)S(8) cluster is the result of the interplay between shifts in the Mo d-band and S p-band and its unique cagelike geometry.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19877650.001).
  • [ISSN] 1520-5215
  • [Journal-full-title] The journal of physical chemistry. A
  • [ISO-abbreviation] J Phys Chem A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Chen C, Pankow JF: Gas/particle partitioning of two acid-base active compounds in mainstream tobacco smoke: nicotine and ammonia. J Agric Food Chem; 2009 Apr 8;57(7):2678-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As K(p)(nic) decreases as a result of the increasing basicity in the MTS, there is an increase in volatility of nicotine from the smoke particulate matter.
  • The water content of MTS particulate matter was found to affect both K(p)(nic) and K(p)(amm).

  • Hazardous Substances Data Bank. NICOTINE .
  • Hazardous Substances Data Bank. Ammonia .
  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Agric Food Chem. 2010 Aug 25;58(16):9287-8; author reply 9289 [20677754.001]
  • [ErratumIn] J Agric Food Chem. 2010 Aug 25;58(16):9289
  • (PMID = 19284716.001).
  • [ISSN] 1520-5118
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acids; 0 / Smoke; 0 / Solutions; 059QF0KO0R / Water; 6M3C89ZY6R / Nicotine; 7664-41-7 / Ammonia
  •  go-up   go-down


59. Robu ME, Larson JD, Nasevicius A, Beiraghi S, Brenner C, Farber SA, Ekker SC: p53 activation by knockdown technologies. PLoS Genet; 2007 May 25;3(5):e78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Morpholino phosphorodiamidate antisense oligonucleotides (MOs) and short interfering RNAs (siRNAs) are commonly used platforms to study gene function by sequence-specific knockdown.
  • Using the zebrafish embryo as a template, correct and mistargeting effects are readily discernible through direct comparison of MO-injected animals with well-studied mutants.
  • We show here indistinguishable off-targeting effects for both maternal and zygotic mRNAs and for both translational and splice-site targeting MOs.
  • We show here that MO off-targeting results in induction of a p53-dependent cell death pathway. p53 activation has also recently been shown to be an unspecified off-target effect of siRNAs.


60. Ditschkowski M, Elmaagacli AH, Trenschel R, Steckel NK, Koldehoff M, Beelen DW: No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis. Biol Blood Marrow Transplant; 2006 Dec;12(12):1350-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.
  • [MeSH-major] Amino Acid Substitution. Hematopoietic Stem Cell Transplantation / statistics & numerical data. Janus Kinase 2 / genetics. Mutation, Missense. Point Mutation. Polycythemia Vera / genetics. Primary Myelofibrosis / genetics. Thrombocythemia, Essential / genetics

  • Genetic Alliance. consumer health - Myelofibrosis.
  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162218.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


61. Hsu HC: Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders. J Chin Med Assoc; 2007 Mar;70(3):89-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.
  • The molecular pathogenesis of chronic myeloproliferative disorders (MPDs) is poorly understood.
  • Recently, 4 groups reported almost simultaneously Janus kinase 2 (JAK2) V617F mutation in more than 80% of PV patients, 30% of patients with ET and in about 50% of patients with idiopathic myelofibrosis.
  • [MeSH-major] Janus Kinase 2 / genetics. Mutation. Myeloproliferative Disorders / etiology
  • [MeSH-minor] Chronic Disease. Humans. Polycythemia Vera / diagnosis. Polycythemia Vera / genetics. Polycythemia Vera / therapy. Thrombocythemia, Essential / diagnosis. Thrombocythemia, Essential / genetics. Thrombocythemia, Essential / therapy

  • Genetic Alliance. consumer health - Chronic Myeloproliferative Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17389152.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 38
  •  go-up   go-down


62. Vannucchi AM, Guglielmelli P, Rambaldi A, Bogani C, Barbui T: Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. J Cell Mol Med; 2009 Aug;13(8A):1437-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.
  • The classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), which include polycythaemia vera, essential thrombocythaemia and primary myelofibrosis, originate from a stem cell-derived clonal myeloproliferation that manifests itself with variable haematopoietic cell lineage involvement; they are characterized by a high degree of similarities and the chance to transform each to the other and to evolve into acute leukaemia.
  • Their molecular pathogenesis has been associated with recurrent acquired mutations in janus kinase 2 (JAK2) and myeloproliferative leukemia virus oncogene (MPL).
  • On the other hand, evidence of abnormal epigenetic gene regulation as a mechanism potentially contributing to the pathogenesis and the phenotypic diversity of MPNs is still scanty; however, study of epigenetics in MPNs represents an active field of research.
  • [MeSH-major] Epigenesis, Genetic. Leukemia / drug therapy. Leukemia / genetics. Myeloproliferative Disorders / drug therapy. Myeloproliferative Disorders / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522842.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 175
  • [Other-IDs] NLM/ PMC3828857
  •  go-up   go-down


63. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, Skoda RC: Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood; 2008 Apr 15;111(8):3931-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An acquired somatic mutation in the JAK2 gene (JAK2-V617F) is present in the majority of patients with myeloproliferative disorders (MPDs).
  • Several phenotypic manifestations (polycythemia vera [PV], essential thrombocythemia [ET], and primary myelofibrosis) can be associated with the same mutation.
  • Induction of the JAK2-V617F transgene with the interferon-inducible MxCre resulted in expression of JAK2-V617F approximately equal to wild-type Jak2 and a PV-like phenotype with increased hemoglobin, thrombocytosis, and neutrophilia.
  • Higher levels of JAK2-V617F in mouse bone marrow by retroviral transduction caused a PV-like phenotype without thrombocytosis.
  • [MeSH-major] Janus Kinase 2 / metabolism. Mutant Proteins / metabolism. Myeloproliferative Disorders / enzymology. Myeloproliferative Disorders / pathology. Phenylalanine / genetics. Valine / genetics
  • [MeSH-minor] Animals. Colony-Forming Units Assay. Granulocytes / enzymology. Hematopoiesis, Extramedullary. Humans. Hyperplasia. Integrases / metabolism. Megakaryocytes / enzymology. Megakaryocytes / pathology. Mice. Mice, Transgenic. Phenotype. Polycythemia Vera / enzymology. Polycythemia Vera / pathology. Primary Myelofibrosis / enzymology. Primary Myelofibrosis / pathology. Recombination, Genetic. Thrombocythemia, Essential / enzymology. Thrombocythemia, Essential / pathology. Transgenes


64. Suyanı E, Akı SZ, Yegin ZA, Ozkurt ZN, Altındal S, Akyürek N, Yaǧcı M, Sucak GT: The impact of bone marrow fibrosis on the outcome of hematopoietic stem cell transplantation. Transplant Proc; 2010 Sep;42(7):2713-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of bone marrow fibrosis on the outcome of hematopoietic stem cell transplantation.
  • We retrospectively analyzed the data of 175 patients who underwent autologous (n = 69) or allogeneic hematopoietic stem cell transplantation (HCT) (n = 106) including 19 (27.5%) and 38 (35.8%) recipients who had bone marrow fibrosis (BMF) prior to transplantation, respectively.
  • We investigated the effects of BMF on engraftment, graft-versus-host disease (GVHD), early posttransplant complications, and survival.
  • Pretransplantation BMF did not delay engraftment and showed no impact either on early posttransplant complications or on the development of acute and/or chronic GVHD.
  • Probability of 1-year overall survival (OS) and progression-free survival (PFS) of autologous HCT recipients were similar, namely 76.7% versus 88.6% (P > .005) and 26.33% versus 16.5% (P > .05) among patients with versus without fibrosis, respectively.
  • In allogeneic HCT recipients, the probability of 1-year OS was 35.2% among patients with versus 48.9% among those without fibrosis (P = .004) PFS at 1 year was inferior among allogeneic HCT recipients with BMF: 27.8% versus 51.2% (P = .0008).
  • Cox regression analysis revealed BMF to be independently associated with age, Sorror comorbidity index, primary disease, and disease status during HCT (P = .045).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Primary Myelofibrosis / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Graft vs Host Disease / epidemiology. HLA Antigens / immunology. Humans. Male. Middle Aged. Neoplasms / surgery. Retrospective Studies. Transplantation Conditioning / methods. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20832575.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


65. Linardi Cda C, Pracchia LF, Buccheri V: Diagnosis and treatment of polycythemia vera: Brazilian experience from a single institution. Sao Paulo Med J; 2008 Jan 2;126(1):52-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of polycythemia vera: Brazilian experience from a single institution.
  • CONTEXT AND OBJECTIVE: Polycythemia vera (PV) is a chronic myeloproliferative disorder characterized by predominant proliferation of erythroid precursors.
  • The aim of this study was to describe clinical and demographic characteristics of PV patients at diagnosis and analyze their long-term outcomes.
  • DESIGN AND SETTING: Retrospective study at the Division of Hematology, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo.
  • Clinical and demographic characteristics, thrombotic events, transformation to acute leukemia, myelofibrosis and survival were evaluated.
  • Thirty-six (54.5%) were females, with a median age at diagnosis of 61 years.
  • At diagnosis, the median hemoglobin concentration was 18.8 mg/dl and the median platelet count was 593,000/mm(3).
  • The overall incidence of leukemia and myelofibrosis was 0.42% per patient-year and 1.06% per patient-year, respectively.
  • [MeSH-major] Polycythemia Vera / diagnosis. Polycythemia Vera / therapy

  • Genetic Alliance. consumer health - Polycythemia vera.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425288.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Hemoglobins
  •  go-up   go-down


66. Park D, Xiong YL, Alderton AL, Ooizumi T: Biochemical changes in myofibrillar protein isolates exposed to three oxidizing systems. J Agric Food Chem; 2006 Jun 14;54(12):4445-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oxidation was induced by incubating the protein suspension at 4 degrees C for 24 h with (i) a hydroxyl radical-generating system (HRGS: 10 microM FeCl3, 0.1 mM ascorbic acid, and 0.05-5.0 mM H2O2), (ii) a lipid-oxidizing system (LOS: 0.05-5.0 mM linoleic acid and 3750 units of lipoxidase/mL), or (iii) a metmyoglobin-oxidizing system (MOS: 0.05-0.5 mM metmyoglobin).
  • The carbonyl content in MOS-treated MPI was the highest, while the TBARS production, changes in thermal properties, and loss of the myosin heavy chain were the greatest in HRGS-treated MPIs.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756379.001).
  • [ISSN] 0021-8561
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cross-Linking Reagents; 0 / Muscle Proteins; 0 / Thiobarbituric Acid Reactive Substances; 12772-23-5 / Metmyoglobin; 3352-57-6 / Hydroxyl Radical; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.3.8 / Calcium-Transporting ATPases; EC 3.6.4.1 / Myosin Heavy Chains; EC 3.6.4.1 / Myosins; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


67. Xylinas E, Ouzaid I, Durand X, Ploussard G, Salomon L, Gillion N, Vordos D, Hoznek A, Abbou CC, de la Taille A: Robot-assisted laparoscopic sacral colpopexy: initial experience in a high-volume laparoscopic reference center. J Endourol; 2010 Dec;24(12):1985-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At a mean follow-up of 19.1 months (range 8-28 mos), no recurrence of the prolapse occurred.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20932190.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Lapasset L, Pradet-Balade B, Vergé V, Lozano JC, Oulhen N, Cormier P, Peaucellier G: Cyclin B synthesis and rapamycin-sensitive regulation of protein synthesis during starfish oocyte meiotic divisions. Mol Reprod Dev; 2008 Nov;75(11):1617-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While rapamycin affected the global protein synthesis, the drug altered neither the specific translation of cyclin B mRNA nor the expression of the Mos protein.

  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18361417.001).
  • [ISSN] 1098-2795
  • [Journal-full-title] Molecular reproduction and development
  • [ISO-abbreviation] Mol. Reprod. Dev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin B; 0 / Eukaryotic Initiation Factor-4E; 0 / Protein Synthesis Inhibitors; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


69. Yu A, Zhang Z, Bi Q, Sun B, Su W, Guan Y, Mu R, Miao C, Zhang J, Yu B: Regulation of cAMP on the first mitotic cell cycle of mouse embryos. Mol Reprod Dev; 2008 Mar;75(3):489-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the downstream of cAMP/PKA, there are some effectors such as polo-like kinase 1 (Plk1), Cdc25, Mos (mitogen-activated protein kinase kinase kinase), MEK (mitogen-activated protein kinase kinase), mitogen-activated protein kinase (MAPK), Wee1, anaphase-promoting complex (APC), and phosphoprotein phosphatase that are involved in the regulation of MPF activity.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 18022836.001).
  • [ISSN] 1098-2795
  • [Journal-full-title] Molecular reproduction and development
  • [ISO-abbreviation] Mol. Reprod. Dev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Proto-Oncogene Proteins; E0399OZS9N / Cyclic AMP; EC 2.7.- / Protein Kinases; EC 2.7.1.- / histone H1 kinase; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / polo-like kinase 1; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  •  go-up   go-down


70. Demin AA, Aksenova EA: [Efficacy of isosorbide-5-mononitrate retard in patients with stable exertional angina]. Klin Med (Mosk); 2005;83(9):53-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study shows that IMN is an effective and safe antianginal agent in treatment of patients with stable angina: it decreased the frequency of anginal attacks (from 4.1 +/- 0.34 to 0.8 +/- 0.13 per day, p < 0.0001), and additional nitroglycerin intake (from 2.2 +/- 0.32 to 0.2 +/- 0.05 tablets per day, p < 0.0001); according to the results of 24-hour ECG monitoring, it reduced ST-segment depression (from 2.2 +/- 0.17 to 0.9 +/- 0.09, p < 0.0001), preventing episodes of painful and silent myocardial ischemia (from 3.5 +/- 0.37 to 2.1 +/- 0.31, p < 0.0001); increased life quality as demonstrated by evaluation of physical (from 19.7 +/- 2.2 to 45.7 +/- 2.22, p < 0.0001), and mental (from 30.9 +/- 2.67 to 57.5 +/- 2.67, p < 0.0001) components using MOS-SF 36 questionnaire.

  • MedlinePlus Health Information. consumer health - Angina.
  • Hazardous Substances Data Bank. ISOSORBIDE DINITRATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16279042.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0 / Vasodilator Agents; 16051-77-7 / isosorbide-5-mononitrate; IA7306519N / Isosorbide Dinitrate
  •  go-up   go-down


71. Martínez SE, Yuan L, Lacza C, Ransom H, Mahon GM, Whitehead IP, Hake LE: XGef mediates early CPEB phosphorylation during Xenopus oocyte meiotic maturation. Mol Biol Cell; 2005 Mar;16(3):1152-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • XGef and CPEB interact during oogenesis and oocyte maturation and are present in a c-mos messenger ribonucleoprotein (mRNP).
  • XGef overexpression increases the level of CPEB phosphorylated early during oocyte maturation, and this directly correlates with increased Mos protein accumulation and acceleration of meiotic resumption.
  • Overexpression of a guanine exchange deficient version of XGef, which interacts with CPEB, does not enhance early CPEB phosphorylation.
  • Overexpression of a version of XGef that has significantly reduced interaction with CPEB, but retains guanine exchange activity, decreases early CPEB phosphorylation and delays oocyte maturation.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2231-6 [12574519.001]
  • [Cites] Mol Cell Biol. 1999 Nov;19(11):7759-70 [10523665.001]
  • [Cites] Dev Biol. 2003 Mar 15;255(2):383-98 [12648498.001]
  • [Cites] Nat Cell Biol. 2002 Apr;4(4):294-301 [11912491.001]
  • [Cites] J Cell Sci. 2000 Apr;113 ( Pt 7):1127-38 [10704364.001]
  • [Cites] Dev Biol. 2000 Apr 1;220(1):97-109 [10720434.001]
  • [Cites] Prog Cell Cycle Res. 2000;4:131-43 [10740821.001]
  • [Cites] Nature. 2000 Mar 16;404(6775):302-7 [10749216.001]
  • [Cites] Curr Biol. 2000 Apr 20;10(8):430-8 [10801413.001]
  • [Cites] Cell. 2000 Sep 1;102(5):625-33 [11007481.001]
  • [Cites] Curr Opin Cell Biol. 2000 Dec;12(6):666-75 [11063930.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12607-12 [11050156.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14358-63 [11114187.001]
  • [Cites] Nature. 2000 Dec 7;408(6813):682-8 [11130063.001]
  • [Cites] Int Rev Cytol. 2001;203:567-608 [11131527.001]
  • [Cites] Dev Biol. 2001 Mar 15;231(2):447-58 [11237472.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Jul;2(7):521-9 [11433366.001]
  • [Cites] J Mass Spectrom. 2001 Oct;36(10):1083-91 [11747101.001]
  • [Cites] Mol Cell. 2000 Nov;6(5):1253-9 [11106762.001]
  • [Cites] EMBO J. 2002 Apr 2;21(7):1833-44 [11927567.001]
  • [Cites] Genes Dev. 2002 Jul 1;16(13):1587-609 [12101119.001]
  • [Cites] J Biol Chem. 2003 Jan 24;278(4):2236-41 [12426316.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(5):1703-16 [12588989.001]
  • [Cites] Genes Dev. 2003 Mar 15;17(6):683-710 [12651887.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21439-49 [12670933.001]
  • [Cites] Cell. 2003 Jul 25;114(2):215-27 [12887923.001]
  • [Cites] Cell. 2003 Dec 26;115(7):893-904 [14697206.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17650-9 [14752101.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] J Virol. 1973 Aug;12(2):241-52 [4747985.001]
  • [Cites] Genes Dev. 1991 Sep;5(9):1697-708 [1653174.001]
  • [Cites] Cell. 1994 Nov 18;79(4):617-27 [7954828.001]
  • [Cites] Nature. 1995 Apr 6;374(6522):511-6 [7700377.001]
  • [Cites] J Biol Chem. 1995 Aug 4;270(31):18388-95 [7629163.001]
  • [Cites] EMBO J. 1995 Nov 15;14(22):5597-607 [8521817.001]
  • [Cites] EMBO J. 1996 May 15;15(10):2582-92 [8665866.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Bioessays. 1997 Jan;19(1):13-21 [9008413.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6419-26 [9343404.001]
  • [Cites] Science. 1998 Jun 26;280(5372):2112-4 [9641916.001]
  • [Cites] J Biol Chem. 1998 Jul 3;273(27):16739-47 [9642229.001]
  • [Cites] Cell. 1998 Oct 16;95(2):269-77 [9790533.001]
  • [Cites] Nat Struct Biol. 1998 Dec;5(12):1098-107 [9846881.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):1990-9 [10022886.001]
  • [Cites] EMBO J. 1999 Apr 15;18(8):2294-303 [10205182.001]
  • [Cites] Genes Dev. 1999 Aug 15;13(16):2177-89 [10465793.001]
  • [Cites] Development. 1999 Oct;126(20):4537-46 [10498688.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2237-42 [12601167.001]
  • (PMID = 15635100.001).
  • [ISSN] 1059-1524
  • [Journal-full-title] Molecular biology of the cell
  • [ISO-abbreviation] Mol. Biol. Cell
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM064702; United States / NCI NIH HHS / CA / CA-77493; United States / NIGMS NIH HHS / GM / R01-GM64702
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cpeb1 protein, Xenopus; 0 / Guanine Nucleotide Exchange Factors; 0 / RNA, Messenger; 0 / Recombinant Proteins; 0 / Transcription Factors; 0 / XGef protein, Xenopus; 0 / Xenopus Proteins; 0 / mRNA Cleavage and Polyadenylation Factors; 4G7DS2Q64Y / Progesterone; 63231-63-0 / RNA; EC 2.5.1.18 / Glutathione Transferase; EC 2.7.- / Protein Kinases; EC 2.7.1.- / histone H1 kinase; EC 3.6.1.- / GTP Phosphohydrolases
  • [Other-IDs] NLM/ PMC551481
  •  go-up   go-down


72. Kleopa KA, Elman LB, Lang B, Vincent A, Scherer SS: Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain; 2006 Jun;129(Pt 6):1570-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Peripheral nerve hyperexcitability is the chief manifestation of acquired neuromyotonia; the combination of neuromyotonia with autonomic and CNS involvement is called Morvan's syndrome (MoS); and CNS manifestations without peripheral involvement is called limbic encephalitis (LE).
  • To determine the cellular basis of these clinical manifestations, we immunostained mouse neural tissues with sera from patients with neuromyotonia (n = 10), MoS (n = 2) or LE (n = 5), comparing with specific antibodies to relevant K+ channel subunits.
  • Again, LE sera labelled Kv1.1 subunits more prominently than did MoS or neuromyotonia sera, suggesting an association between higher Kv1.1 specificity and limbic manifestations.
  • These studies support the hypothesis that antibodies to mature surface membrane-expressed Shaker-type K+ channels cause acquired neuromyotonia, MoS and LE, and suggest that future assays based on immunofluorescence of cells expressing individual Kv1 subunits will prove more sensitive than the immunoprecipitation assay.

  • Genetic Alliance. consumer health - Limbic encephalitis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613892.001).
  • [ISSN] 1460-2156
  • [Journal-full-title] Brain : a journal of neurology
  • [ISO-abbreviation] Brain
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS43174
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers; 0 / KCNA6 protein, human; 0 / Kv1.2 Potassium Channel; 0 / Shaker Superfamily of Potassium Channels; 147173-20-4 / Kv1.1 Potassium Channel
  •  go-up   go-down


73. Bousquet M, Le Guellec S, Quelen C, Rigal-Huguet F, Delsol G, Brousset P: Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations. Hum Pathol; 2006 Nov;37(11):1458-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
  • A retrospective investigation of the JAK2 V617F mutation was carried out in DNA samples from 131 bone marrow (BM) core biopsy specimens corresponding to patients with polycythemia vera (PV) (n = 31), essential thrombocythemia (ET) (n = 31), chronic idiopathic myelofibrosis (CIM) (n = 18), as well as patients with normal BM and secondary reactive hyperplasia.
  • [MeSH-major] Bone Marrow / chemistry. Janus Kinase 2 / genetics. Myeloproliferative Disorders / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Female. Humans. Male. Middle Aged. Point Mutation. Polycythemia Vera / genetics. Polymerase Chain Reaction. Primary Myelofibrosis / genetics. Retrospective Studies. Thrombocythemia, Essential / genetics

  • Genetic Alliance. consumer health - Chronic Myeloproliferative Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Hum Pathol. 2007 Oct;38(10):1581-2 [17889678.001]
  • (PMID = 16949922.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


74. Bahr S, Borodin A, Höfft O, Kempter V, Allouche A: Interaction of formic acid with solid water. J Chem Phys; 2005 Jun 15;122(23):234704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastable impact electron spectroscopy and ultraviolet photoemission spectroscopy (He I and II) were utilized to study the electron emission from the 10a' to 6a' molecular orbitals (MOs) of FA, and the 1b(1), 3a(1), and 1b(2) MOs of H(2)O.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008470.001).
  • [ISSN] 0021-9606
  • [Journal-full-title] The Journal of chemical physics
  • [ISO-abbreviation] J Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Mørcke AM, Wichmann-Hansen G, Eika B: [Aarhus University--a step towards outcome-based education]. Ugeskr Laeger; 2008 Oct 27;170(44):3525-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Aarhus University--a step towards outcome-based education].
  • [Transliterated title] Aarhus Universitet på vej mod målrettet uddannelse.
  • In 2007 the Faculty of Health Sciences, Aarhus University, took a first step towards outcome-based education.
  • During an educational development process, all courses developed clear, consistent descriptions of learning outcomes and extensive, template-based course descriptions.
  • This enabled the Faculty to implement a new national grading system and to prepare for Aarhus University's application for an ECTS label.
  • Furthermore, the process created the basis for alignment of outcomes, assessment and teaching.
  • In this paper, we share results, problems encountered and lessons learned.
  • [MeSH-major] Competency-Based Education. Education, Medical
  • [MeSH-minor] Clinical Competence. Denmark. Educational Measurement. Faculty, Medical. Humans. Learning. Teaching / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976614.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


76. Setty H, Rawlings JL, Dubin S: Video RIFL: a rigid flexible laryngoscope to facilitate airway management. J Clin Anesth; 2010 Dec;22(8):642-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is a novel stylet-based laryngoscope that incorporates a complementary metal oxide sensor distal chip imaging system and real-time articulation tip.


77. Gao Y, Mu N, Xu XP, Wang Y: Porcine acute liver failure model established by two-phase surgery and treated with hollow fiber bioartificial liver support system. World J Gastroenterol; 2005 Sep 21;11(35):5468-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The BALSS constructed with high volume recirculating technique was a hollow fiber circulating system consisting of a hepatocyte reactor-hollow fiber module inoculated with microcarrier-adhering hepatocytes, and a double pump, heparinized, thermostabilized, micro-capsulized activated carbon-adsorbing plasmapheresis system.
  • After 3 h of phase II surgery, ammonia (Amm) increased to (269+/-37) micromol/L.
  • After 9 h of surgery, ALB and Cr were (27+/-4) g/L and (87+/-9) micromol/L.
  • The comparison analysis between the treated and control animals showed the changes of Tbil, PT, Alb, BUN, Cr, Fib, and Amm (P<0.01), but there was no change of ALT and AST.
  • [MeSH-minor] Alanine Transaminase / blood. Animals. Aspartate Aminotransferases / blood. Disease Models, Animal. Hepatocytes / metabolism. Hepatocytes / pathology. Liver, Artificial. Swine

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222738.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  • [Other-IDs] NLM/ PMC4320355
  •  go-up   go-down


78. Corella F, Barnadas MA, Bordes R, Curell R, Espinosa I, Vergara C, Alomar A: [A case of cutaneous extramedullary hematopoiesis associated with idiopathic myelofibrosis]. Actas Dermosifiliogr; 2008 May;99(4):297-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of cutaneous extramedullary hematopoiesis associated with idiopathic myelofibrosis].
  • [Transliterated title] Hematopoyesis extramedular cutánea en mielofibrosis idiopática: a propósito de un caso.
  • Cutaneous extramedullary hematopoiesis is a rare manifestation of chronic myeloproliferative processes, mainly chronic idiopathic myelofibrosis.
  • The lesions usually appear soon after diagnosis and the possibility of a relationship between splenectomy and the appearance of extramedullary foci of hematopoiesis is still debated.
  • Diagnosis is based on histopathology showing an infiltrate with different combinations of myeloid and erythroid cell precursors and megakaryocytes.
  • Symptomatic treatment is provided alongside treatment of the underlying disease.
  • We report a new case associated with chronic idiopathic myelofibrosis in which foci of cutaneous extramedullary hematopoiesis were observed 9 years after initial diagnosis.
  • The lesions were progressive and the patient went on to develop acute myeloid leukemia.
  • [MeSH-major] Hematopoiesis, Extramedullary. Primary Myelofibrosis / complications. Skin Physiological Phenomena

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394406.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


79. Mwongela SM, Siminialayi N, Fletcher KA, Warner IM: A comparison of ionic liquids to molecular organic solvents as additives for chiral separations in micellar electrokinetic chromatography. J Sep Sci; 2007 Jun;30(9):1334-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Common CE buffers, mixed with a molecular micelle, and an IL or a MOS, were used for these chiral separations.
  • However, a current break down was observed for the buffers containing more than 60% v/v MOS on application of the above-mentioned electric field.
  • The chiral resolution and selectivity of the analytes were dependent on the concentration and type of IL or MOS used.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BENZOIN .
  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • Hazardous Substances Data Bank. METHANOL .
  • Hazardous Substances Data Bank. ACETONITRILE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17623476.001).
  • [ISSN] 1615-9306
  • [Journal-full-title] Journal of separation science
  • [ISO-abbreviation] J Sep Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 1-butyl-3-methylimidazolium tetrafluoroborate; 0 / 1-ethyl-3-methylimidazolium tetrafluoroborate; 0 / Acetonitriles; 0 / Borates; 0 / Imidazoles; 0 / Ionic Liquids; 0 / Naphthalenes; 0 / Organophosphates; 0 / Solvents; 35193-63-6 / 1,1'-binaphthyl-2,2'-diyl hydrogen phosphate; 9Y8NXQ24VQ / Propranolol; L7J6A1NE81 / Benzoin; Y4S76JWI15 / Methanol; Z072SB282N / acetonitrile
  •  go-up   go-down


80. Quagraine EK, Georgakaki I, Coucouvanis D: Reactivity and kinetic studies of (NH4)2(MoS4) in acidic aqueous solution: possible relevance to the angiostatic function of the MoS4(2-) ligand. J Inorg Biochem; 2009 Jan;103(1):143-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although addition of mineral acids to WS(4)(2-) in water is known to lead to aggregation and formation of various polynuclear thiotungstate anions, acid hydrolysis of the MoS(4)(2-) anion is reported to give mainly MoS(3) or MoS(2) as hydrolysis products.
  • Knowledge of the resulting product(s) from such reactions has implications on the use of tetrathiomolybdate (MoS(4)(2-)) as both a potential anti-tumor drug and for the treatment of Wilson's disease.
  • In this investigation, reaction of HCl with MoS(4)(2-) in water was monitored as a function of time.
  • Reaction mixtures of both 1:1 and 2:1 mole ratios of the acid to MoS(4)(2-) were examined, as well as MoS(4)(2-) reactions in simulated human stomach fluids at pH of approximately 2 and 3.

  • Hazardous Substances Data Bank. MOLYBDENUM .
  • Hazardous Substances Data Bank. HYDROGEN CHLORIDE .
  • Hazardous Substances Data Bank. Water .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19026449.001).
  • [ISSN] 1873-3344
  • [Journal-full-title] Journal of inorganic biochemistry
  • [ISO-abbreviation] J. Inorg. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Ligands; 0 / Solutions; 059QF0KO0R / Water; 81AH48963U / Molybdenum; 91U3TGV99T / tetrathiomolybdate; QTT17582CB / Hydrochloric Acid
  •  go-up   go-down


81. Cortelezzi A, Gritti G, Del Papa N, Pasquini MC, Calori R, Gianelli U, Cortiana M, Parati G, Onida F, Sozzi F, Vener C, Bianchi P, Deliliers GL: Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia; 2008 Mar;22(3):646-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status.
  • [MeSH-major] Endothelial Cells / pathology. Hypertension, Pulmonary / etiology. Neovascularization, Pathologic / complications. Primary Myelofibrosis / complications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow / blood supply. Cell Count. Disease Progression. Dyspnea / etiology. Fatigue / etiology. Female. Humans. Male. Middle Aged. Polycythemia Vera / complications. Prevalence. Thrombocythemia, Essential / complications


82. Bain BJ: Blood film features of primary myelofibrosis. Am J Hematol; 2009 Mar;84(3):187
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood film features of primary myelofibrosis.
  • [MeSH-major] Megakaryocytes / pathology. Primary Myelofibrosis / pathology

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18980175.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Wang JC: Importance of plasma matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinase (TIMP) in development of fibrosis in agnogenic myeloid metaplasia. Leuk Lymphoma; 2005 Sep;46(9):1261-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of plasma matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinase (TIMP) in development of fibrosis in agnogenic myeloid metaplasia.
  • Bone marrow fibrosis in AMM, with deposition, not only of interstitial and basement membrane collagen but also of fibronectin, vitronectin, laminin and proteoglycans, results from a disturbed balance between synthesis and proteolytic degradation of matrix protein.
  • Although TIMP and MMP play important roles in the development of fibrosing diseases of skin, liver and lung, only a few studies of TIMP and MMP in the formation of bone marrow fibrosis in AMM have been published.
  • The literature shows that TIMP-1 (both the total, complex and the free form) is significantly increased in AMM and other myeloproliferative syndromes (including polycythemia vera (PV) and essential thrombocytosis (ET)), while MMP-3 is significantly decreased, and levels of MMP-2 and MMP-9 are not different from control values.
  • Variance from control values for both TIMP-1 and MMP-3 is more evident in AMM than in PV and ET, thus further suggesting bone marrow fibrosis in AMM results from enhanced TIMP and decreased MMP activities.
  • [MeSH-major] Matrix Metalloproteinases / physiology. Primary Myelofibrosis / etiology. Primary Myelofibrosis / pathology. Tissue Inhibitor of Metalloproteinases / physiology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109602.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 69
  •  go-up   go-down


84. Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D: The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol; 2005 Nov;131(3):320-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
  • An association between an activating JAK2 mutation (JAK2(V617F)) and BCR/ABL-negative myeloproliferative disorders was recently reported in multiple simultaneous publications.
  • In the current study, mutation analysis for JAK2(V617F) was performed in peripheral blood mononuclear cells (PBMC) from 157 patients with myelofibrosis with myeloid metaplasia (MMM) including 117 with agnogenic (AMM), 22 with postpolycythaemic (PPMM), and 18 with post-thrombocythaemic (PTMM) myeloid metaplasia.
  • The detection rate for JAK2(V617F) was significantly higher in PPMM (91%; homozygous in 18%) compared with either AMM (45.3%; homozygous in 2.6%) or PTMM (38.9%; homozygous in 11.1%).
  • In AMM, the presence of JAK2(V617F) was associated with an older age at diagnosis and a history of thrombosis or pruritus.
  • In conclusion, JAK2(V617F) is a myeloid lineage-specific event, its incidence in MMM is significantly higher with an antecedent history of polycythaemia vera (PV), and its presence in AMM does not affect prognosis but is associated with PV-characteristic clinical features.
  • [MeSH-major] Mutation. Primary Myelofibrosis / genetics. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins / genetics

  • Genetic Alliance. consumer health - Myelofibrosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16225651.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


85. Porensky EK, Dew MA, Karp JF, Skidmore E, Rollman BL, Shear MK, Lenze EJ: The burden of late-life generalized anxiety disorder: effects on disability, health-related quality of life, and healthcare utilization. Am J Geriatr Psychiatry; 2009 Jun;17(6):473-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The burden of late-life generalized anxiety disorder: effects on disability, health-related quality of life, and healthcare utilization.
  • OBJECTIVE: To describe the burden of Generalized Anxiety Disorder (GAD), a common anxiety disorder in older adults.
  • PARTICIPANTS: One hundred sixty-four older adults with GAD and 42 healthy comparison participants with no lifetime history of psychiatric disorder were recruited from primary care and mental health settings as well as advertisements.
  • MEASUREMENTS: Participants were evaluated with the Late Life Function and Disability Index to assess disability, the MOS 36-Item Short Form Survey Instrument to assess health-related quality of life (HRQOL), and the Cornell Service Index to assess healthcare utilization.
  • CONCLUSION: This study, the largest ever of GAD in older adults, provides evidence of the significant burden of this disorder in late life.
  • Given the high prevalence and chronicity of GAD in the elderly, these data provide a public health imperative for finding and implementing effective management strategies for this typically undiagnosed and untreated disorder.

  • Genetic Alliance. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Depression.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Behav Res Ther. 1990;28(6):487-95 [2076086.001]
  • [Cites] J Psychiatr Res. 1975 Nov;12(3):189-98 [1202204.001]
  • [Cites] Med Care. 1994 Jan;32(1):40-66 [8277801.001]
  • [Cites] J Affect Disord. 1997 Apr;43(2):105-19 [9165380.001]
  • [Cites] Health Care Financ Rev. 1997 Spring;18(3):43-59 [10173123.001]
  • [Cites] Am J Psychiatry. 1997 Dec;154(12):1734-40 [9396954.001]
  • [Cites] Psychol Med. 1997 Nov;27(6):1397-409 [9403911.001]
  • [Cites] Int J Geriatr Psychiatry. 1998 Oct;13(10):717-26 [9818308.001]
  • [Cites] Psychol Med. 1999 May;29(3):583-93 [10405079.001]
  • [Cites] Br J Med Psychol. 1959;32(1):50-5 [13638508.001]
  • [Cites] Am J Geriatr Psychiatry. 2005 Jan;13(1):31-9 [15653938.001]
  • [Cites] Am J Geriatr Psychiatry. 2005 Jan;13(1):77-80 [15653943.001]
  • [Cites] Am J Geriatr Psychiatry. 2005 Feb;13(2):150-6 [15703324.001]
  • [Cites] Am J Psychiatry. 2005 Jun;162(6):1179-87 [15930067.001]
  • [Cites] Psychiatr Serv. 2005 Dec;56(12):1564-9 [16339619.001]
  • [Cites] Stat Med. 2006 Feb 28;25(4):591-602 [16143965.001]
  • [Cites] Depress Anxiety. 2006;23(2):77-82 [16411185.001]
  • [Cites] J Cardiopulm Rehabil Prev. 2007 Mar-Apr;27(2):86-91 [17558244.001]
  • [Cites] J Affect Disord. 2007 Nov;103(1-3):77-82 [17321595.001]
  • [Cites] Am J Geriatr Psychiatry. 2008 Jan;16(1):5-13 [18165458.001]
  • [Cites] Depress Anxiety. 2008;25(1):72-90 [17146763.001]
  • [Cites] Depress Anxiety. 2008;25(1):27-37 [17238158.001]
  • [Cites] Am J Psychiatry. 1999 Dec;156(12):1915-23 [10588405.001]
  • [Cites] Acta Psychiatr Scand. 2000 Jan;101(1):29-36 [10674948.001]
  • [Cites] Psychol Med. 2000 May;30(3):657-68 [10883720.001]
  • [Cites] Int Clin Psychopharmacol. 2000 Nov;15(6):319-28 [11110007.001]
  • [Cites] Int J Psychiatry Med. 2001;31(2):183-98 [11760862.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2002 Apr;57(4):M209-16 [11909885.001]
  • [Cites] J Gen Intern Med. 2002 Mar;17(3):165-72 [11929501.001]
  • [Cites] Psychol Med. 2002 May;32(4):649-59 [12102379.001]
  • [Cites] Int J Methods Psychiatr Res. 2002;11(3):99-111 [12459823.001]
  • [Cites] J Consult Clin Psychol. 2003 Feb;71(1):31-40 [12602423.001]
  • [Cites] Behav Res Ther. 2003 Apr;41(4):481-7 [12643969.001]
  • [Cites] J Consult Clin Psychol. 2003 Apr;71(2):309-19 [12699025.001]
  • [Cites] J Psychiatr Res. 2004 May-Jun;38(3):305-12 [15003436.001]
  • [Cites] Br J Soc Clin Psychol. 1967 Dec;6(4):278-96 [6080235.001]
  • [Cites] Psychiatry Res. 1992 Mar;41(3):237-48 [1594710.001]
  • (PMID = 19472438.001).
  • [ISSN] 1545-7214
  • [Journal-full-title] The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • [ISO-abbreviation] Am J Geriatr Psychiatry
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / P30 MH071944; United States / NIMH NIH HHS / MH / R01 MH070547; United States / NIMH NIH HHS / MH / P30 MH71944
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS387541; NLM/ PMC3408215
  •  go-up   go-down


86. Arai T, Obuchi S, Inaba Y, Nagasawa H, Shiba Y, Watanabe S, Kimura K, Kojima M: The effects of short-term exercise intervention on falls self-efficacy and the relationship between changes in physical function and falls self-efficacy in Japanese older people: a randomized controlled trial. Am J Phys Med Rehabil; 2007 Feb;86(2):133-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The subjects in the exercise intervention group performed an exercise program for 3 mos.

  • MedlinePlus Health Information. consumer health - Falls.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17251695.001).
  • [ISSN] 0894-9115
  • [Journal-full-title] American journal of physical medicine & rehabilitation
  • [ISO-abbreviation] Am J Phys Med Rehabil
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


87. Morel P, Duhamel A: Comparison of prognostic scoring systems in primary myelofibrosis. Blood; 2010 Jan 21;115(3):745; author reply 745-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of prognostic scoring systems in primary myelofibrosis.
  • [MeSH-major] Primary Myelofibrosis / diagnosis

  • Genetic Alliance. consumer health - Myelofibrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Blood. 2009 Mar 26;113(13):2895-901 [18988864.001]
  • (PMID = 20093412.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comment; Comparative Study; Letter
  • [Publication-country] United States
  •  go-up   go-down


88. Rorison P, Thomlinson A, Hassan Z, Roberts SA, Ferguson MW, Shah M: Longitudinal changes in plasma Transforming growth factor beta-1 and post-burn scarring in children. Burns; 2010 Feb;36(1):89-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, high systemic levels of Transforming growth factor beta1 have generally been associated with fibrotic disease processes such as myelofibrosis and pulmonary fibrosis.

  • MedlinePlus Health Information. consumer health - Burns.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd and ISBI. All rights reserved.
  • (PMID = 19524370.001).
  • [ISSN] 1879-1409
  • [Journal-full-title] Burns : journal of the International Society for Burn Injuries
  • [ISO-abbreviation] Burns
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


89. Eyigor S, Karapolat H, Durmaz B, Ibisoglu U, Cakir S: A randomized controlled trial of Turkish folklore dance on the physical performance, balance, depression and quality of life in older women. Arch Gerontol Geriatr; 2009 Jan-Feb;48(1):84-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Outcome measures included a 20-m walk test, a 6-min walk test, stair climbing and chair rise time, Berg balance scale (BBS), the Medical Outcomes Study (MOS) 36-item short form health survey (SF-36), and geriatric depression scale (GDS) questionnaires.

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Depression.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068829.001).
  • [ISSN] 1872-6976
  • [Journal-full-title] Archives of gerontology and geriatrics
  • [ISO-abbreviation] Arch Gerontol Geriatr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  •  go-up   go-down


90. Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G: Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood; 2006 Feb 1;107(3):880-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
  • To characterize acute megakaryocytic leukemia (FAB M7 AML), we identified 37 patients with M7 AML treated at M.D.
  • Anderson Cancer Center between 1987 and 2003 and compared them with 1800 patients with non-M7, non-M3 AML treated during the same period.
  • The median age of the M7 AML group was 56 years (range, 21-78 years); 22 patients (59%) had an antecedent hematologic disorder or myelodysplastic syndrome or both, and 7 patients (19%) had previously received chemotherapy for other malignancies.
  • Extensive bone marrow fibrosis was found in 23 patients (62%).
  • Complete remission rates were 43% with M7 AML and 57% with non-M7 AML (P = .089).
  • Median disease-free survivals were 23 versus 52 weeks, respectively (P < .001).
  • These results confirm the poor prognosis of M7 AML and indicate that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this disease.
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Multivariate Analysis. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / pathology. Myelodysplastic Syndromes / therapy. Neoplasms. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Primary Myelofibrosis / mortality. Primary Myelofibrosis / pathology. Primary Myelofibrosis / therapy. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123215.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL, Paul B, Harrison CN, Green AR, Campbell PJ: Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood; 2008 Jan 01;111(1):60-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes.
  • The role of histopathology in the diagnosis of essential thrombocythemia (ET) is controversial, and there has been little attempt to quantitate interobserver variability.
  • Diagnostic bone marrow trephine biopsy specimens from 370 patients with ET by Polycythemia Vera Study Group (PVSG) criteria were assessed by 3 experienced hematopathologists for 16 different morphologic features and overall diagnosis according to the World Health Organization (WHO) classification.
  • Our results show substantial interobserver variability, particularly for overall diagnosis and individual cellular characteristics such as megakaryocyte morphology.
  • One factor related to overall and lineage-specific cellularity and was significantly associated with JAK2 V617F status (P < .001), a second factor related to megakaryocyte clustering, and a third was associated with the fibrotic process.
  • No differences could be discerned between patients labeled as having "prefibrotic myelofibrosis" or "true ET" in clinical and laboratory features at presentation, JAK2 status, survival, thrombosis, major hemorrhage, or myelofibrotic transformation.
  • These results show that histologic criteria described in the WHO classification are difficult to apply reproducibly and question the validity of distinguishing true ET from prefibrotic myelofibrosis on the basis of subjective morphologic criteria.
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Aspirin / therapeutic use. Biopsy. Blood Cell Count. Drug Therapy, Combination. Humans. Hydroxyurea / therapeutic use. Megakaryocytes / pathology. Observer Variation. Platelet Aggregation Inhibitors / therapeutic use. Primary Myelofibrosis / classification. Primary Myelofibrosis / drug therapy. Primary Myelofibrosis / pathology. Prospective Studies. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885079.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN72251782
  • [Grant] United Kingdom / Wellcome Trust / / 088340; United Kingdom / Cancer Research UK / / 8961; United Kingdom / Medical Research Council / / G0300497
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platelet Aggregation Inhibitors; 0 / Quinazolines; K9X45X0051 / anagrelide; R16CO5Y76E / Aspirin; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


92. Schroeder SL, Weiher N: F K-edge X-ray absorption near-edge structure (XANES) of AlF3 polymorphs: combining ab initio calculations with Walsh correlation diagrams. Phys Chem Chem Phys; 2006 Apr 21;8(15):1807-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The X-ray absorption near-edge structures (XANES) at the F K-edge of alpha-AlF(3), beta-AlF(3) and a tetragonal AlF(3) phase are analysed by a combination of ab initio calculations with the FEFF8 code and a phenomenological discussion of local molecular orbital (MO) symmetries at the absorbing fluorine atoms.
  • By means of a Walsh correlation diagram it is shown that the two intense absorption bands observed at the F K-edges of the AlF(3) polymorphs can be interpreted as transitions to anti-bonding MOs in [Al-F-Al]-units that have C(2v) and D(infinity h) point group symmetries.
  • The interpretation in terms of local MOs provides for the first time a "chemically intuitive" approach to investigations of solid fluorides by XANES spectroscopy and provides a simple conceptual framework for the discussion of the electronic structure in AlF(3) materials.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. ALUMINUM FLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633665.001).
  • [ISSN] 1463-9076
  • [Journal-full-title] Physical chemistry chemical physics : PCCP
  • [ISO-abbreviation] Phys Chem Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Ions; 0 / Macromolecular Substances; Q80VPU408O / Fluorides; Z77H3IKW94 / aluminum fluoride
  •  go-up   go-down


93. Vegas A, Santamaría-Pérez D, Marqués M, Flórez M, García Baonza V, Recio JM: Anions in metallic matrices model: application to the aluminium crystal chemistry. Acta Crystallogr B; 2006 Apr;62(Pt 2):220-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The central idea is the conception of the crystal structure of such an inorganic compound as a metallic matrix whose geometric and electronic structures govern the formation and localization of the anions in the lattice.
  • This is the reason for labelling the model anions in metallic matrices (AMM).
  • Taking the AlX3 crystal family (X = F, Cl, OH) as a suitable test-bed class of compounds, we illustrate how this approach gives a direct interpretation of the crystalline structures and explains the variable coordination that Al exhibits in crystalline materials.
  • An exhaustive analysis of the topology of the electron density allows us to provide a quantum-mechanical assessment of the main hypotheses of the AMM model and to uncover, using microscopic arguments, the behavior of anions as chemical pressure agents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552155.001).
  • [ISSN] 0108-7681
  • [Journal-full-title] Acta crystallographica. Section B, Structural science
  • [ISO-abbreviation] Acta Crystallogr., B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


94. Emadi S, Clay D, Desterke C, Guerton B, Maquarre E, Charpentier A, Jasmin C, Le Bousse-Kerdilès MC, French INSERM Research Network on MMM: IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. Blood; 2005 Jan 15;105(2):464-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis.
  • Myeloproliferation, myelofibrosis, and neoangiogenesis are the 3 major intrinsic pathophysiologic features of myeloid metaplasia with myelofibrosis (MMM).
  • The myeloproliferation is characterized by an increased number of circulating CD34+ progenitors with the prominent amplification of dystrophic megakaryocytic (MK) cells and myeloid metaplasia in the spleen and liver.
  • Our results suggest that IL-8 and its receptors participate in the altered MK growth that features MMM and open new therapeutic prospects for this still incurable disease.
  • [MeSH-major] Interleukin-8 / blood. Megakaryocytes / cytology. Primary Myelofibrosis / physiopathology. Receptors, Interleukin-8A / metabolism. Receptors, Interleukin-8B / metabolism

  • Genetic Alliance. consumer health - Myelofibrosis.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15454487.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD34; 0 / Interleukin-8; 0 / Receptors, Interleukin-8A; 0 / Receptors, Interleukin-8B
  •  go-up   go-down


95. Gui Y, Xie C, Xu J, Wang G: Detection and discrimination of low concentration explosives using MOS nanoparticle sensors. J Hazard Mater; 2009 May 30;164(2-3):1030-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection and discrimination of low concentration explosives using MOS nanoparticle sensors.
  • In the present study, four explosives of NH(4)NO(3), mineral explosives (ME), picric acid (PA) and 2,6-dinitrotoluene (2,6-DNT) have been investigated by using ZnO-doped nanoparticle sensors with additives of Sb(2)O(3), TiO(2), V(2)O(5) and WO(3).
  • Firstly, eighteen ZnO-doped nanoparticle sensors were optimized and selected six best sensors to compose a new optimized array.
  • Then, the detection capability of the sensor array was studied by using static sampling method.
  • The results showed that with the increase in concentration of samples, the sensitivities of the sensors also increased, and the lowest detection limit of the four samples were low to 3.34 microg/L.
  • [MeSH-minor] Dinitrobenzenes / analysis. Nitrates / analysis. Optics and Photonics. Picrates / analysis. Zinc Oxide

  • Hazardous Substances Data Bank. Ammonium picrate .
  • Hazardous Substances Data Bank. ZINC OXIDE .
  • Hazardous Substances Data Bank. DINITROTOLUENE .
  • Hazardous Substances Data Bank. 2,6-DINITROTOLUENE .
  • Hazardous Substances Data Bank. AMMONIUM NITRATE .
  • Hazardous Substances Data Bank. Picric acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18930348.001).
  • [ISSN] 1873-3336
  • [Journal-full-title] Journal of hazardous materials
  • [ISO-abbreviation] J. Hazard. Mater.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Dinitrobenzenes; 0 / Explosive Agents; 0 / Nitrates; 0 / Picrates; A49OS0F91S / picric acid; GG7FAV92MK / 2,6-dinitrotoluene; SOI2LOH54Z / Zinc Oxide; T8YA51M7Y6 / ammonium nitrate
  •  go-up   go-down


96. Nordling Nilson L, Karlson B, Nise G, Malmberg B, Orbæk P: Delayed manifestations of CNS effects in formerly exposed printers--a 20-year follow-up. Neurotoxicol Teratol; 2010 Nov-Dec;32(6):620-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed manifestations of CNS effects in formerly exposed printers--a 20-year follow-up.
  • Whether long-term occupational exposure to organic solvents may affect mental and cognitive functioning later in life, remains unclear.
  • In this study, twelve rotogravure printers formerly exposed to toluene and 19 referents, all initially examined in the mid-1980s, were reexamined after twenty years, applying neuropsychological tests, symptoms and social interaction questionnaires, medical examination, and exposure assessment of each individual's cumulative exposure.
  • By far the most extensive exposure, mainly toluene, had occurred before 1985.
  • The printers were found to have deteriorated more than their referents in cognitive functioning affecting reasoning and associative learning.
  • No relevant additional exposure during the lengthy time period between assessments could explain this discrepancy.
  • In addition, printers performed significantly worse than the referents in verbal memory and sustained attention at follow-up, where also a dose-effect relationship was noted for reasoning.
  • While the printers did not report more subjective cognitive complaints than the referents, a slightly higher depression score was noted for the printers.
  • The findings of significantly worse deteriorations in cognitive functioning in previously toluene-exposed printers are in line with our hypothesis that sub-clinical deficits during the working life may become manifest later in life, indicating that exposure may in fact interact with ageing.
  • However, considering the small study groups the results must be interpreted with caution.
  • [MeSH-major] Brain / drug effects. Cognition / drug effects. Occupational Exposure / adverse effects. Printing. Solvents / toxicity. Toluene / toxicity
  • [MeSH-minor] Follow-Up Studies. Humans. Male. Neuropsychological Tests. Surveys and Questionnaires. Time Factors

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. TOLUENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20580817.001).
  • [ISSN] 1872-9738
  • [Journal-full-title] Neurotoxicology and teratology
  • [ISO-abbreviation] Neurotoxicol Teratol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Solvents; 3FPU23BG52 / Toluene
  •  go-up   go-down


97. Haririan A, Morawski K, West MS, El-Amm JM, Doshi MD, Cincotta E, Alangaden GJ, Chandrasekar P, Gruber SA: Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients. Clin Transplant; 2007 Jul-Aug;21(4):466-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • D+/R- patients received valganciclovir 900 mg/d and CMV + patients 450 mg/d for three months.
  • RESULTS: A total of 14 Cases with CMV infection and 129 Controls were identified for primary analysis, and 11 D+/R- Cases and 19 D+/R- Controls for secondary analysis.
  • The groups were comparable in both analyses, except for D+/R- serostatus in the primary analysis.
  • All 14 Cases were on TCL for at least three months prior to diagnosis of CMV infection.
  • In the primary analysis, zero Cases, but 30.2% and 34.9% of Controls (p = 0.009 and 0.004), and in secondary analysis, zero Cases, but 31.6% and 42.1% of Controls (p = 0.046 and 0.013), were on SRL at one and three months, respectively.
  • In the primary analysis, zero Cases vs. 45 Controls (p = 0.004), and in secondary analysis, zero Cases vs. eight Controls (p = 0.013), were on SRL for at least three months early post-transplantation.
  • CONCLUSION: These findings suggest that SRL as a component of a multidrug immunosuppressive regimen decreases the risk of CMV infection after kidney transplantation when compared with TCL.

  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645705.001).
  • [ISSN] 0902-0063
  • [Journal-full-title] Clinical transplantation
  • [ISO-abbreviation] Clin Transplant
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


98. Mesa RA: Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs; 2010 Jun;13(6):394-403
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.
  • Ruxolitinib was initially developed to target the constitutive activation of the JAK-STAT pathway in patients with myeloproliferative neoplasms (MPNs).
  • Meaningful reductions in spleen size and constitutional symptoms have been noted in patients with myelofibrosis (both primary and post-essential thrombocythemia/polycythemia vera).
  • [MeSH-major] Janus Kinase 1 / antagonists & inhibitors. Janus Kinase 2 / antagonists & inhibitors. Multiple Myeloma / drug therapy. Myeloproliferative Disorders / drug therapy. Psoriasis / drug therapy. Pyrazoles

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20506062.001).
  • [ISSN] 2040-3410
  • [Journal-full-title] IDrugs : the investigational drugs journal
  • [ISO-abbreviation] IDrugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / INCB018424; 0 / Pyrazoles; EC 2.7.10.2 / Janus Kinase 1; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


99. Periyasamy G, Burton NA, Hillier IH, Thomas JM: Electron delocalization in the metallabenzenes: a computational analysis of ring currents. J Phys Chem A; 2008 Jul 3;112(26):5960-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have analyzed 21 metallabenzenes using variations of these techniques, which take account of the large core and metal orbital contributions which often lead to transition-metal-containing systems exhibiting anomalous shielding values.
  • Analysis of individual orbital contributions to both the ring currents and chemical shielding values based upon the ipsocentric and CSGT (continuous set of gauge transformations) methods has shown that complexes such as the 18 electron Ir or Rh(C 5H 5)(PH 3) 2Cl 2 molecules should be classed as aromatic, whereas the 16 electron complexes such as Os or Ru(C 5H 5)(PH 3) 2Cl 2 should not, despite having the same occupancy of pi-MOs.


100. Loutfy MR, Harris M, Raboud JM, Antoniou T, Kovacs C, Shen S, Dufresne S, Smaill F, Rouleau D, Rachlis A, Gough K, Lalonde R, Tsoukas C, Trottier B, Walmsley SL, Montaner JS: A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration. HIV Med; 2007 Oct;8(7):427-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Questionnaires to assess the incidence and severity of ISRs (31-item score) and QoL [Medical Outcomes Study HIV Health Survey (MOS-HIV)] were administered at baseline and following a minimum of 14 days of Biojector use.
  • CONCLUSIONS: Compared with needles, the Biojector was associated with a decreased severity of ISRs and improved QoL in patients taking enfuvirtide.






Advertisement